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General introduction

General introduction
1.1 History
The actual condition of psoriasis was first described by the Greek physician 
Hippocrates, who lived between 460 and 377 BC. He described a skin condition 
resembling psoriasis, but this was clubbed together with diseases like leprosy, 
eczema and tubercular lupus.
Psoriasis was again mentioned In the first century by Cornelius Celsus (25 BC - 
50 AD), a Roman author. Celsus described It as the fourth variant of Impetigo. 
Joseph Jacob Plenck (Vienna, 1776) wrote of psoriasis as being amongst the 
group of scaly diseases. He also did not study In-depth to differentiate the 
condition from other skin diseases.
Finally, the English dermatologist Robert W lllan (1757 - 1812) recognized psoriasis 
as an Independent entity and for almost a century, psoriasis was known as 
W lllan ’s lepra.
He Identified two categories: Leprosa Graecorum was the term he used to 
describe the condition when the skin had scales. Psora Leprosa described the 
condition when It became eruptive. In 1841, Ferdinand Hebra, a Viennese 
dermatologist who was working on W lllan ’s notes, ascribed the name “psoriasis” 
(from the Greek word “psora” which means “to Itch”) In the English dictionary. 
He described the clinical picture of psoriasis that Is used today.13
1.2 Epidemiology
Psoriasis Is a chronic relapsing non-lnfectlous Inflammatory skin disorder, which 
affects approximately 1.5-3%  of the adult Caucasian populatlon.4J5The occurrence 
Is most frequent In Europeans and Scandinavians, uncommon In Chinese and 
non-existent In Samoans or Latin American Indians.5:7
Prevalence rates of childhood psoriasis have been published In two reports. 
In 2007, a prevalence rate of 0.55% was found In the first age decade and 1.37% 
In the second age decade.4Two years later, another study was published reporting 
comparable figures of 0.37% In the first age decade and 1.01% In the second age 
decade. The total prevalence of psoriasis In children up to 18 years was 0.71%.8
Data about the age of onset of psoriasis vary among Investigators. Age of onset 
before the age of 20 years Is reported In 27 - 50% of all psoriatic patients.915 In 10 -15% 
of patients with psoriasis, the disease started before the age of 10 years.11:14:15
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In 1985, two peak ages of onset were found by Henseler and Christophers17: one 
at 16 - 22 years and one at 60 years. These peaks have been confirmed In one 
other study18, but several other authors claim that there are no peaks10;19 and that 
prevalence Increases In an approximately linear m atter8. Henseler and Christophers 
also stated that two clinical forms of psoriasis could be distinguished, one with an 
early age of onset (< 40 years of age) and one with a late age of onset (> 40 years 
of age).17 According to the authors, psoriasis of early onset was found to follow an 
Irregular course with frequent relapses. More patients had extensive body 
Involvement and nail Involvement, and genetic factors seemed to play a prominent 
role. On the other hand, late onset psoriasis followed a more stable clinical course, 
and extensive body and nail Involvement were less frequently observed. Henseler 
and Christophers also postulated that In this form, genetic factors seem to be 
more secondary. The above described differences between the two groups were 
also seen by Ferrandlz et al.20 Nevertheless, the separation of the two groups has 
been questioned by many others who promote that early onset and late onset 
psoriasis cannot be distinguished on clinical grounds.15- 123
Most authors agree on the fact that the male to female ratio In juvenile psoriasis 
Is equal.19;24~29 On the other side, some cohorts consist of more women than men 
with juvenile psoriasis, with ratios up to 2.3 : 1.30-34 In adult psoriasis, the male to 
female ratio Is equal.5:5
In 4.5 - 71% of children with psoriasis a positive family history of psoriasis Is 
noted.20;24-35 The highest rates are found In European and Australian populations25"13, 
the lowest In Indian and Chinese com m unities2429. The same wide variation In 
familial distribution Is found In adults with psorlasls.10;20;35‘38
1.3 Clinical features
Classic lesions of psoriasis consist of round, erythematous, well-marglnated 
plaques covered by a characteristic greyish or sllvery-whlte (mlca-llke or 
“m icaceous”) scale. Typical signs of psoriasis are the “signe de tache de bougie”, 
which refers to the candle wax-llke appearance of a plaque when Its scales are 
being scratched, and the “Auspltz’ sign”, which refers to pinpoint bleedings that 
become visible after removing the silvery scales.3:39 Lesions most Invariably begin 
as small, reddish, pinpoint to plnhead-slzed papules surmounted by fine scales.
12
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These papules coalesce and form patches or plaques that measure one centimeter 
or more In diameter.
All of the clinical variants of psoriasis described In adults are recognized In 
childhood.25
Plaque psoriasis Is the most common variant In the juvenile population, with 
frequencies varying from 54.1 to 89.2%.19;24;2522;34;35;40 In children, plaques are often 
smaller and thinner, and the scale Is finer and softer than In adults. In 1975, a 
cohort of juvenile psoriasis patients was analyzed In which only 18% had plaque 
psoriasis33, but this Is out of line with all other recent and larger studies.
Guttate psoriasis Is the second most frequently seen subtype In childhood 
psoriasis. It often develops suddenly, often In response to a streptococcal throat 
Infection. It Is characterized by the eruption of multiple papules of 0.5 -1 centimeter 
In diameter over the face, trunk and limbs. There Is a tendency for this variety of 
psoriasis to resolve spontaneously, although a substantial proportion of patients 
will go on to develop chronic plaque disease.4143 Reported frequencies of guttate 
psoriasis He between 6.4 - 44%.1*;24-2*;31-35;40
Pustular psoriasis Is rare In children. Four clinical patterns of pustular psoriasis 
have been described In children: generalized pustular psoriasis (also known as 
von Zumbusch pattern), annular pustular psoriasis, exanthematlc pustular 
psoriasis and localized pustular psoriasis.4447 Several studies have reported 
that annular pustular psoriasis Is the most common form of juvenile pustular 
psoriasis.45:47 Frequencies of juvenile pustular psoriasis vary w idely between 
studies. Most authors report a frequency of approximately 1 - 2%19;242527;312:5, but 
others report a frequency around 10%29;3°.
Erythroderm ie psoriasis In children Is a very rare form of psoriasis that presents 
as erythema covering most of the body surface. Scaling Is less prominent than 
with plaque psoriasis. Frequencies are reported from 0.7 - 5.1 %.24;26;27;2-'"32
The most frequently Involved sites In childhood psoriasis are the extremities, 
although also the scalp and trunk are frequently Involved.19;26;28;30;32 35 In children, the 
face Is more frequently affected than In adults, with numbers ranging from 17 - 
56.7%.192528:30:332:5 Nall changes are observed In up to 40% of children with psoriasis. 
Fingernails are more commonly Involved than toenails. Most common Is pitting of 
the nails, but all other types of nail Involvement such as onycholysis, subungual 
hyperkeratosis, discoloration, longitudinal striae and ridging can be observed.192426“ 
33;35;4o prur¡t¡s ¡s seen In up to 87% of all juvenile psoriasis patients.24:26:28:29:32:33:35
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Psoriatic arthropathy is seen in 0.7 - 2.9% of juvenile psoriatis patients.24;25;27;29;35 
The exact incidence of juvenile psoriatic arthritis is unknown, but estimates 
extrapolated from population studies suggest a prevalence of 10 to 15 per 
100 000 children.48 50 In a substantial proportion of juvenile patients (23 - 58%) 
arthritis precedes psoriasis.5154 In contrast, adult psoriatic arthritis usually 
presents with many years of psoriasis before the onset of arthritis.55 57 The onset 
of psoriatic arthritis in children is often between the ages of 7 and 13 years. Distal 
interphalangeal joints of hands and feet, knees and ankles may be involved 
during the early stages. Over time, polyarthritis may develop to include wrist, 
metacarpophalangeal, elbow and metatarsophalangeal jo in ts.55
Predisposing factors for childhood psoriasis include a genetic background58, 
a positive family history58, group A ß-haemolytic streptococcal infections30);44, 
traum a59, drugs (e.g. anti-m alarials)50 and stress30);51. Also, seasonal influences 
are seen, mostly with lesions worsening during the winter.24;25;29;31;33 
In one study, juvenile psoriasis has been associated with increased rates of 
hyperlipidaemia, obesity, hypertension, diabetes mellitus, rheumatoid arthritis 
and C rohn’s disease.8 Up to now, there is no consensus if obesity is a risk factor 
for the onset of juvenile psoriasis.52:53
1.4 Histopathology
The superficial layers of the epidermis are characterized by absence of the 
granular layer and presence of remnants of nuclei w ithin the horny layer (confluent 
parakeratosis). The accumulation of polymorphonuclear leukocytes in the stratum 
spinosum (spongiform micro-pustules of Kogoj) and the formation of infiltrates of 
polymorphonuclear leukocytes in the stratum corneum (micro-abscesses of 
Munro), are considered to be psoriasis specific.
The epidermis is thickened (acanthosis) with a thinned suprapapillary plate. Rete 
ridges are elongated, slim and approximately the same length. The abnormalities 
in the dermis consist of vasodilatation and tortuousity of the capillaries together 
w ith a mixed inflammatory infiltrate consisting of T-lymphocytes and polym orpho­
nuclear leukocytes.54
14
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1.5 Aetiology
Childhood psoriasis is a multifactorial disease. Both genetic and environmental 
factors participate in the risk of psoriasis. Up to 70% of paediatric patients have a 
family history of psoriasis and affected tw ins have been described. The life-time 
risk of developing psoriasis is thought to be 4% if no parent is affected, 28% if one 
parent is affected and 65% if both parents are affected.55 Genetic susceptibility 
has been linked to class I and class II major histocompatibility complexes on 
chromosome 6. Two disease subsets have been proposed, differing in both age 
of onset and the human leukocyte antigen (HLA) present. Type I represents early 
onset psoriasis (onset < 40 years of age) and has been linked to HLA-Cw6, B57 
and DR7. Type II represents late onset psoriasis (onset > 40 years of age) and 
has been linked to HLA-Cw2.35 Nine genetic susceptibility loci (PSORS1 - 9) have 
been detected by linkage analysis, but the genetic determinants at these loci 
have not all been identified yet. The susceptibility locus w ith the greatest genetic 
effect (PSORS1) lies on chromosome 6p21.3 in the region of the major histocom ­
patibility complex.55
Laboratory studies, clinical observations and use of targeted therapy gathered 
evidence that psoriasis is an immune-mediated disorder. The majority of T-cells in 
psoriatic plaques are CD45RO+ memory-effector T-cells that migrate into skin 
exposed to an antigenic trigger. Th1 cytokines, particularly interferon-y and IL-2, 
predominate, in contrast to the largely Th2 cytokine response of the acute lesions 
of atopic dermatitis.67 Furthermore, Th17 is a T-cell subset to be of major importance 
in the pathogenesis of psoriasis. Th17-cel Is are activated by IL-23, which is a 
cytokine produced by dendritic cells upon activation. Anti-IL12/23p40 antibodies 
have been shown to have an outstanding therapeutic activity in adult psoriasis.68:69 
Recently, it has been demonstrated that not only T-cells have a role in the 
pathogenesis of psoriasis. The absence of two members of the late cornified 
envelope (LCE) gene cluster (LCE3B and LCE3C) is significantly associated with 
risk of psoriasis. Even more, LCE is strongly expressed in psoriatic lesions, 
suggesting that compromised skin barrier function has a role in psoriasis.70
1.6 Treatment
In the treatment of adult patients w ith psoriasis, a spectrum of topical treatments, 
photo(chemo)therapy, conventional systemic treatments and biologies is available.
15
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For children with psoriasis most of these treatments are not registered. Only a few 
clinical trials in children with psoriasis have been performed.7172 As children are 
not just small adults, results of trials in adults cannot simply be extrapolated to 
children.
Since 26 January 2007, the Paediatric Regulation is effective in the European 
Union.73 This has changed the procedure for obtaining marketing authorisation of 
medicines in Europe so that new medications can be adapted safely for the use 
in children. Additional provisions have been made for the use of authorised and 
generic medications in children. Research is being stimulated through grants and 
the extension of exclusive distribution rights for manufacturers. Other initiatives 
are aimed at making existing data on the use of medications in children accessible. 
Many of these tasks are the responsibility of a special European paediatric 
committee, which also assesses proposals for research on medication use in 
children.74
Successful management of childhood psoriasis requires education of the child 
and parents about the nature of the disease and the treatment options. Patients 
and their parents must understand the chronicity of the disease and have to learn 
to accept that there is no permanent cure for psoriasis.
It is important to tailor treatment to the patient’s needs, considering their age and 
the extent, severity and location of the condition. The approach to medication 
should be made as simple as possible, since therapy is time-consuming, 
burdensome and easily rejected.57 Especially in young children, compliance is 
dependent almost entirely on the parents.
Treatment of childhood psoriasis should intend to control the disease, rather than 
to achieve complete clearance. Of course, it is also important to consider short- 
and long-term safety profiles and the risk-to-benefit ratio for any treatment. 
Regrettably, guidelines on the treatment of juvenile psoriasis are lacking. The 
American Academy of Dermatologists briefly mentions the paediatric use of 
anti-psoriatic medication in their guideline concerning the treatment of psoriasis. 
Unfortunately, no treatment algorithm is suggested. A Dutch guideline is currently 
in preparation and will soon arrive. Treatment options for children w ith psoriasis 
are mostly based on expert opinions rather than evidence. The evidence on 
efficacy and safety of separate treatment options in children with psoriasis will be 
discussed in Chapter 3 of this thesis.
The following treatments are currently used for the treatment of childhood 
psoriasis (although most of them are not registered for this indication): emollients,
16
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keratolytics, topical corticosteroids, vitam in Dq analogues, calcineurin inhibitors, 
dithranol, phototherapy, retinoids, ciclosporin, methotrexate and biologies. 
Emollients moisturize and soften the skin and can be used to reduce redness, 
itching and pain of psoriatic lesions.
Keratolytics (e.g. salicylic acid) are used to descale thick hyperkeratotic plaques 
and can therefore improve penetration of other topical treatments. Especially in 
children, it should be used with caution because it may induce salicylic acid 
intoxication.75
Topical corticosteroids are probably the most frequently prescribed first-line 
treatment for psoriasis and have an anti-inflammatory, immunosuppressive and 
anti-m itotic effect.75 Topical corticosteroids can be divided into four potency 
classes: class I (low potent) to class IV (ultra potent). The side effects of topical 
corticosteroids include epidermal atrophy (usually irreversible), dermal atrophy 
with the development of striae (especially in intertriginous zones), perioral 
dermatitis and steroid rosacea. Systemic absorption of corticosteroids can lead 
to suppression of the pituitary-adrenal axis, especially with class IV cortico­
steroids.77
Topical vitam in Dq analogues are frequently used as the therapy of choice for mild 
to moderate psoriasis. In The Netherlands two synthetic vitam in Dq analogues are 
available: calcipotriol (Daivonex®) and calcitriol (Silkis®). Vitamin Da analogues 
are usually well tolerated, but irritation of the skin may occur. To prevent effects on 
the calcium metabolism, a maximal dose of 100 gram calcipotriol per week is 
recommended for adults. For adults, the body surface has an average of 2 m2. 
Consequently, the recommended maximum dose per m2 per week is 50 gram. 
For children, the recommended maximum dose per week can be found by 
calculating the body surface of the child (body surface (m2) = V((length(cm)*- 
weight(kg))/3600)) and multiplying it by 50 gram. This calculation was performed 
in a randomized controlled trial in children and no effects on the calcium 
metabolism were found.71
Topical calcineurin inhibitors can be used especially in facial and intertriginous 
psoriasis. Available formulations are tacrolimus ointment 0.03% or 0.1% (Protopic®) 
and pimecrolimus 1% cream (Elidel®). In contrast to corticosteroids, they do not 
cause atrophy and tachyphylaxis. The most frequently seen side effects are 
irritation and stinging after application. A lthough there is a theoretical concern 
that topical im munomodulatory therapy with tacrolimus and pimecrolimus may 
increase the risk of cancer, there is no evidence to date to suggest an increased 
risk of cutaneous or visceral cancer.78 Nevertheless, the European Medicines
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Agency (EMA) advises to use topical calcineurin inhibitors with great caution in 
order to reduce potential risks of skin cancer and lymphoma as far as possible. 
Dithranol is one of the oldest topical therapeutics for psoriasis. The exact 
mechanism of action is still unknown, but it is known to induce a cascade of free 
radicals in the skin, resulting in antiproliferative effects and a modulation of 
inflammation in psoriasis.79 No serious side effects of dithranol have been 
reported.80 It may cause a burning sensation, irritation and staining at the 
application site or clothing.
Phototherapy with ultraviolet B (UVB) and photochemotherapy with ultraviolet A 
(UVA) following ingestion or topical treatment with psoralen are two classical 
therapies for adult patients w ith moderate to severe psoriasis that does not 
respond to topical therapies alone. In children it is less frequently used than in 
adults. A lthough there are no studies documenting the long-term safety of UVB 
phototherapy in childhood psoriasis, judicious use of this therapy is advised for 
appropriately selected patients (e.g. adolescents whose disease fails to respond 
to topical therapy).81
The term “retinoids” is used for a family of substances of natural and synthetic 
analogues of vitamin A. Acitretin is the only systemic retinoid that is available for 
the treatment of (adult) psoriasis in The Netherlands. Common side effects are 
mucocutaneous problems, e.g. cheilitis, dryness of the eyes, nasal and oral 
mucosa, epistaxis, xerosis, brittle nails, hair loss and burning or sticky skin. 
Increases of serum triglycerides are frequently observed. Attention should also 
be given to the teratogenicity of acitretin.77
Ciclosporin is a calcineurin inhibitor which inhibits T-cell function and thus the 
production of various cytokines. It is mainly used as a short period intervention in 
very severe psoriasis. Dose-dependent renal impairment is the most common 
cause of withdrawal of treatment. As well as renal side effects, hypertension, 
malignancies and infections may occur during treatment with ciclosporin.77 
Methotrexate is a folic acid antagonist, which is often used in severe psoriasis 
unresponsive to topical therapeutics. The most common side effects are nausea, 
malaise, abdominal discomfort, leucopenia and hepatotoxicity. If methotrexate- 
related abdominal d iscomfort occurs, subcutaneous treatment can be 
endeavoured instead of oral ingestion.77
Biologies are the newest agents used for the treatment of psoriasis. Etanercept 
(Enbrel®) is the only biologic that is registered by the EMA for the use in children 
older than eight years with psoriasis. Etanercept isa  soluble tum or necrosis factor 
alpha (TNFa) receptor fusion protein that antagonizes the effects of endogenous
18
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TNFa, which is a protein that promotes an inflammatory response in psoriasis. 
Etanercept is usually well tolerated in paediatric patients with moderate to severe 
plaque psoriasis.82 Injection site reactions can occur, as well as infections, 
common colds, fever and headache. The long-term side effects are not completely 
known, because of the limited experience with this agent. Malignancies (e.g. 
lymphomas) have been reported in children with polyarthritis, juvenile idiopathic 
arthritis, ankylosing spondylitis, vasculitis and psoriatic arthritis that were treated 
with etanercept. It should be noted that most of these patients were also receiving 
previous and concomitant im munosuppressants.83:84 Registries will have to 
provide additional information on this subject.
1.7 Quality of life
The diagnosis of childhood psoriasis raises the question among parents as to the 
extent to which this diagnosis can influence the quality of life of their child now 
and in the future. It is known that having a chronic disease in childhood can 
diminish a child ’s health-related quality of life.85 Negative life experiences, such 
as a chronic disease in childhood, may also have an impact on childhood 
development and adult life.85 In dermatological research, quality of life studies in 
children mainly focus on atopic dermatitis, demonstrating the burden atopic 
dermatitis has on children.85187 89 In view of the comparable impact of atopic 
dermatitis and psoriasis in adult patients90, it could be assumed that childhood 
psoriasis also has a comparable impairing influence on the quality of life for 
children with these skin conditions.
Two previous studies have reported quality of life scores of children with psoriasis.85-’1 
To evaluate the disease-related quality of life the only valid questionnaire available 
for this purpose was used: the Children’s Dermatology Life Quality Index (CDLQI) 
questionnaire.92 In the validation study of the CDLQI questionnaire, 25 patients with 
psoriasis were questioned.91 The mean CDLQI score was 5.4 (SD 5.0), ranging from 
0 to 18 points. In another study, 29 juvenile psoriatic patients filled out the CDLQI 
questionnaire.85 Their mean score was 9.2 (SD 7.8; range 0 - 27). In this study, it 
was also demonstrated that the quality of life of children with psoriasis is even 
worse than in diabetes and epilepsy in childhood.85
Therefore, a child-tailored treatment should not only be optimized to limit disease 
activity, but attention should also be paid to improving the quality of life of children 
with psoriasis.
19
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1.8 Aims of this thesis
The studies carried out in this thesis were set up in order to achieve more insight 
in the epidemiology, treatments and quality of life of childhood psoriasis.
The following aims were formulated: 
la)
to further explore the epidemiology and clinical features of childhood psoriasis in 
The Netherlands 
lb)
to compare differences and sim ilarities between childhood onset psoriasis and 
adult onset psoriasis
to obtain an overview of efficacy and safety of treatment options in childhood 
psoriasis
to create an evidence-based algorithm for the treatment of childhood psoriasis
to get more insight in the psychological burden of psoriasis in children 
lllb)
to compare the burden of psoriasis as experienced in childhood to the burden in 
adulthood
1.9 Clinical approach
CAPTURE reg is try
In 2005, a patient registry was set up by investigators of the Department of 
Dermatology of the Radboud University Nijmegen Medical Centre to collect data 
on efficacy and safety of biological therapies for the treatment of adult patients 
w ith psoriasis in daily clinical practice.93
In September 2008, this registry was expanded to also register prospective data 
(on efficacy and safety of treatments and quality of life) of all juvenile psoriasis 
patients (i.e. < 18 years old) who visit the Department of Dermatology of the 
Radboud University Nijmegen Medical Centre. This expanded prospective 
registry was named “CAPTURE”, an acronym for Continuous Assessment of 
Psoriasis Treatment Use Registry (CAPTURE). Child-CAPTURE is used for the
20
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childhood psoriasis part of the registry, whereas Bio-CAPTURE is used for the 
part in which patients with biological therapies are being followed.
M ethods to  score  p so ria s is  d isease seve rity
The Psoriasis Area and Severity Index (PASI) score is the most frequently used 
measure to characterize the clinical severity of psoriasis. The first description of 
this instrument was published in 1978 by Fredriksson and Petterson94 and it has 
been considered as the golden standard since.95 The PASI scoring system 
assesses four body regions: the head (h), the upper limbs (u), the trunk (t) and the 
lower extremities (I). The extent of psoriatic involvement in these four main body 
areas (Ah, At, Au and Al) is assessed using numbers according to the following 
scale: 0, no involvement; 1, < 10%; 2, 10 - 30%; 3, 31 - 50%; 4, 51 - 70%; 5, 71 - 
90% and 6, 91 - 100%. For each region, erythema (E), induration (I) and 
desquamation (D) were rated according to a five-point scale: 0, no involvement; 
1, slight; 2, moderate; 3, marked and 4, very marked involvement. Subsequently, 
the PASI score is calculated from the following formula: PASI = 0.1Ah (Eh + Ih + 
Dh) + 0.2AU (Eu + lu + Du) + 0.3At (Et + It + Dt) + 0.4AI (El + Il + DI). The PASI 
score can vary in increments of 0.1 units from 0 to 72 with a higher score 
representing a greater severity of psoriasis. A lthough the PASI score ranges from
0 to 72, most patients have scores ranging between 0 and 15. PASI scores of 40 
and higher are sporadically seen.
The severity of psoriasis is also rated with the second most often employed score 
to measure psoriasis severity: the Physician’s Global Assessment (PGA). This 
assessment is easier to perform and less time-consum ing than the PASI score. 
The investigator has to assign a single estimate of the patient’s overall severity of 
disease on an ordinal scale. For all research performed in this thesis, a six-point 
Likert scale is used (0, clear; 1, minimal; 2, mild; 3, moderate; 4, severe; 5, very 
severe). The PGA ranges from 0 to 5.
For questionnaires in adults, the Self-Administered PASI (SAPASI) is used. This is 
a valid and reliable instrument that allows adult patients to assess the severity of 
their psoriasis. The redness, induration and scaliness of an average psoriatic 
lesion are rated with three visual analogue scales (VAS). The involved area of the 
skin is marked on an anatomical sketch and is weighted by an investigator 
according to the original PASI score.95 The range of the SAPASI score is 0 - 72, 
with increasing severity of psoriasis with increasing SAPASI scores. Ranges to 
explain the severity of psoriasis were previously described as: 0, complete 
remission; > 0 - 3 ,  mild; > 3 - 1 5 ,  moderate; > 15, severe.97
21
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The Body Surface Area (BSA) affected is also measured, with a minimum of 0% 
and a maximum of 100%.
Physical symptoms of Itch, pain and fatigue are measured on separate VAS, 
measuring the mean level of Itch, pain and fatigue over the past four weeks (0, no 
Itch /  pain /  fatigue; 10, worst Itch /  pain /  fatigue ever experienced).90
M ethods to  score  qua lity  o f life
Disease-related quality of life Is assessed with the Children’s Dermatology Life 
Quality Index (CDLQI) questionnaire (http://www.dermatology.org.uk/quallty/ 
quallty-cdlql.htm l).91 The CDLQI consists of 10 questions, each with four possible 
replies, scored 0 to 3. The total score Is calculated by summing the score of each 
question resulting In a maximum of 30 and a minimum of 0. The higher the score, 
the more the quality of life Is Impaired. Questlon-categorles are symptoms and 
feelings, dally activities, leisure, work and school, personal relationships and 
treatment.
For assessment of stigmatization a slx-ltem subscale adapted from the Impact of 
Chronic Skin Disease on Dally Life (ISDL) questionnaire Is used. Gauged Is to 
what extent the respondent feels stigmatized by others as a result of his /  her skin 
condition, w ith response categories on a four-point Llkert scale (1, not; 2, a little; 
3, strongly; 4, totally) (Item examples: Others are staring; Others avoid contact). 
The stigmatization score thus ranges from 6 to 24.
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Chapter 2.1
No evidence found that childhood 
onset of psoriasis influences disease 
severity, future body mass index 
or type of treatments used
M.E.A. de Jager, E.M.G.J. de Jong, K.A.P. Meeuwis, 
P.C.M. van de Kerkhof, M.M.B. Seyger
Journal o f the European Academy o f Dermatology and Venereology
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Abstract
Background
In more than one-third of the psoriatic population, the first manifestations occur In 
childhood. W hether the age of onset of psoriasis Influences the march of psoriasis 
Is not known.
Objective
To describe the epidemiology and clinical features as well as prescribed 
treatments and familial distribution In psoriasis depending on the age of onset of 
the disease.
Methods
A structured questionnaire was sent to 5300 adult psoriatic patients. Respondents 
were divided Into two groups: patients who experienced an onset of disease 
before the age of 18 years (childhood onset psoriasis (COP)) and patients with an 
onset of disease from the age of 18 years (adult onset psoriasis (AOP)).
Results
Questionnaires of 1926 patients (36.3%) were suitable for analysis. In 37.1% of 
patients, first signs of the disease occurred before the age of 18 years. COP 
occurs predominantly In females, has a longer delay In diagnosis and a higher 
frequency of familial distribution. The development of guttate and erythrodermlc 
psoriasis In adulthood Is more frequently seen In COP. In contrast to common 
believe, the type of psoriasis In COP often remains the same from childhood to 
adulthood. There was no evidence found that getting psoriasis before the age of 
18 years Influences the development of high body mass Index In adulthood, 
disease severity In later life or type of treatments used.
Conclusions
The age of onset of psoriasis essentially does not Influence the subsequent 
course of the disease In adulthood.
Childhood onset versus adult onset psoriasis
Introduction
Onset of psoriasis in childhood is not uncommon. In more than one-third of the 
psoriatic population, the first manifestations occur in childhood.14 This points out 
the significance of knowledge about childhood onset psoriasis (COP). Studies have 
been conducted to assess the differences between early onset and late onset of 
psoriasis. Following the definition proposed by Henseler and Christophers,5 most 
studies examined the differences in groups with an onset before or after the age 
of 30 years5;7. Only one study has been carried out to demonstrate differences 
between childhood onset (< 16 years) and adult onset of psoriasis.4 
The purpose of the present study was to describe the epidemiology and clinical 
features of psoriasis of childhood and adult onset. Also, prescribed treatments as 
well as familial distribution in both groups were investigated.
Methods
A structured questionnaire was drawn up to assess epidemiology and clinical 
aspects of psoriasis. Patients were asked for age, gender, length, weight, marital 
status, age of onset of psoriasis, age of diagnosis of psoriasis, family history, 
severity of disease, joint/nail involvement and treatment history. A pilot study in 10 
patients was conducted to assess the wording and the order of the questions as 
well as the time needed to complete the questionnaire. In the second phase, the 
questionnaire was sent to all 5300 members of the Dutch Psoriasis Society and 
responses were gathered from 14 February 2009 until 1 June 2009.
Patients were subdivided into two groups depending on the age of onset of 
disease. The first group consisted of patients who experienced an onset before 
the age of 18 years (childhood onset psoriasis (COP)); the second group 
comprised patients with an onset of disease from the age of 18 years (adult onset 
psoriasis (AOP)).
Body Mass Index (BMI) was calculated from current height and weight (BMI = 
weight /  height2). Severity of psoriasis was assessed by a Patient Global 
Assessment (PGA) and the Self-Administered Psoriasis Area and Severity Index 
(SAPASI).8 The PGA was rated on a scale from clear to very severe. The SAPASI 
ranges from a minimum of 0 to a maximum of 72. Treatments used were stratified 
in six different groups: no treatment, emollients, topical 1st line therapy (cortico­
steroids, vitam in D analogues, coal tar and calcipotriol/betamethasone), topical
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2nd line therapy (dithranol and UV-therapy), systemic therapy (methotrexate, 
ciclosporin, retinoids and fumarie acid) and biologies.
S ta tis tica l ana lys is
Descriptive statistics were provided using mean (± SD) and range for numeric 
variables; frequencies and percentages were calculated for categorical variables. 
Missing values were not included to determine percentages. Correlation 
coefficients were calculated for associations between variables. Comparisons of 
numeric variables were analyzed with the (un)paired f-test; the %2test was used to 
compare categorical variables. P-values < 0.002 were considered as statistically 
significant due to Bonferroni’s correction for multiple testing. Statistical analysis 
was performed using SPSS16 (SPSS Inc., Chicago, IL, USA).
Results
Sam ple cha ra c te r is tic s
Of the 5300 questionnaires sent, 1963 (37.0%) were returned. Due to missing 
values in age of onset, questionnaires of 1926 (36.3%) patients were suitable for 
analysis. The mean age of the respondents was 55.8 years (range 1 8 - 9 0  years; 
SD ± 13.4). Among the respondents, 929 (48.2%) were men and 997 (51.8%) were 
women. Mean duration of psoriasis was 30.4 years, ranging from 0 years to 82 
years (SD ± 16). Mean age of onset of psoriasis was 25.5 years; mean age at 
diagnosis of psoriasis was 27.6 years of age. Mean age of onset was 26.8 years 
in men and 24.3 in women (unpaired f-test; p < 0.001). In 37.1% of patients, first 
signs of the disease occurred before the age of 18 years. Adolescent onset (13 - 
18 years) was reported by 18.9% of patients and onset of the disease below the 
age of 13 years by 18.2%.
The total group of 1926 respondents was divided into two groups according to 
the age of onset of psoriasis: the COP-group (onset of psoriasis < 18 years) 
consisted of 715 patients (37.1%) and the AOP-group (onset of psoriasis > 18 
years) comprised 1211 patients (62.9%). Women represented 62.9% of the 
COP-group whereas in the AOP-group 45.2% were women (%2; p < 0.001). Most 
common skin types were types II (37.6%) and III (42.8%). Of the total group of 
respondents, 77.3% were married or cohabiting, whereas 13.2%, 5.9% and 3.6% 
was unmarried, widowed or divorced, respectively. A majority of both groups (> 75%) 
were married or cohabiting when filling out the questionnaire. There was no
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difference between distribution in classes of marital status for COP or AOP (%2; p 
= 0.051). Mean BMI was 26.6 kg/m2 (range 16.3 - 61.7; SD ± 4.6), which is 
regarded as overweight by the World Health Organization (WHO).9 In the study 
population, 39.2% had a normal weight (BMI 18 -25)  and 59.6% were overweight 
(BMI > 25). There was a weak correlation between age of onset and BMI (r = 
0.074; p = 0.001). Moreover, mean BMI was significantly lower in COP than in 
AOP (26.2 (SD ± 4.8) vs. 26.8 (SD ± 4.5); unpaired t-test; p = 0.015).
Type o f pso rias is
Plaque psoriasis was the most frequent current clinical type of psoriasis seen in 
1302 (68.1%) of patients, followed by guttate psoriasis in 727 (38.0%) of patients. 
Erythroderm ie psoriasis and pustular psoriasis were only seen in 7.3% and 5.0% 
of respondents, respectively.
Joint complaints were present in 818 (42.8%) patients. In addition, nail involvement 
was reported by 984 (51.5%) patients. Genital psoriasis was seen in 45.3% of 
respondents, whereas perianal psoriasis was seen in 30.0%. As displayed in 
Table 1, guttate and erythroderm ic psoriasis are more frequently seen in adult life 
if the psoriasis started in childhood (%2; p <0.001). The occurrence of plaque 
psoriasis in adulthood was not statistically different for COP and AOP (%2; p = 
0.213). Joint and nail involvement were seen in equal percentages in both groups. 
There were no significant differences in the prevalence of genital and perianal 
psoriasis in COP and AOP (%2; p = 0.564 and 0.152 respectively). In childhood, 
only 3.5% reported genital psoriasis and 1.4% reported perianal psoriasis. Patients 
with COP had plaque psoriasis approximately twice as much (69.9%) as guttate 
psoriasis (44.2%) in their adult ages. In a majority of patients with COP, the type 
of psoriasis at onset remains the same when the patient grows up. Precise 
percentages are displayed in Table 2.
Severity  o f pso rias is
Patient Global Assessm ent (PGA) of lesions in the past year was indicated as 
clear, minimal, mild, moderate, severe and very severe by 2.7%, 16.7%, 35.0%, 
33.3%, 9.6% and 2.7% of the respondents, respectively (Table 3). Mean current 
SAPASI score was 6.6 (range 0 - 39.4; SD ± 4.4). SAPASI scores of COP and AOP 
were equal (6.9 vs. 6.4; unpaired f-test; p = 0.017). A weak correlation was found 
between age of onset and SAPASI (r = -0.086; p < 0.001). PGA of lesions in the 
past year was not significantly different between both groups (%2; p = 0.089). 
PGA of severity as experienced in childhood was usually mild to moderate.
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Table 1 C lin ica l typ e  of p so rias is
Total Childhood  
onset (COP)
Adult onset 
(AOP)
X 2 test 
p - valui
n % n % n %
Clinical type as adult
Plaque psoriasis 1302 68.1 496 69.9 806 67.1 0.213
Guttate psoriasis 727 38.0 314 44.2 413 34.4 < 0.001'
Pustular psoriasis 95 5.0 28 3.9 67 5.6 0.112
Erythrodermie psoriasis 140 7.3 74 10.4 66 5.5 < 0.001'
Joint involvement 818 42.8 500 42.3 318 43.1 0.708
Nail involvement 984 51.5 376 53.0 608 50.6 0.324
Clinical type as child
Plaque psoriasis 462 67.4
Guttate psoriasis 232 33.9
Pustular psoriasis 16 2.3
Erythrodermie psoriasis 40 5.8
Joint involvement 41 6.0
Nail involvement 96 14.2
Unknown 50 7.3
* Significant value
Table 2 Transition of type of psoriasis from childhood to adulthood in 
childhood onset psoriasis*
Childhood (%)
PP GP PP & GP
Adulthood (%) PP 57.1 15.7 16.7
GP 6.3 48.5 21.8
PP & GP 19.7 26.9 53.8
Other 9.8 5.2 5.1
Unknown 7.1 3.7 2.6
* Numbers presented as percentages of patients 
PP plaque psoriasis 
GP guttate psoriasis
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Table 3 Severity of psoriasis
Total (%) Childhood Adult onset x2 test
onset (COP) (%) (AOP) (%) p -  value
n = 1918 n = 712 n = 1206
Current severity
Clear 2.7 3.1 2.5
Minimal 16.7 16.0 17.1
Mild 35.0 38.6 32.8
Moderate 33.3 29.9 35.3
Severe 9.6 9.4 9.8
Very severe 2.7 2.9 2.5
Severity in childhood n = 695
Clear 0.6
Minimal 12.5
Mild 26.0
Moderate 31.9
Severe 16.8
Very severe 10.4
Unknown 1.7
Transition of severity according to the PGA was examined for COP (Table 4). 
Generally, the severity of psoriasis dim inishes if compared between childhood 
and adulthood (paired f-test; p < 0.001). Transition from a moderate to mild form 
of psoriasis was reported by 13.8% of patients. On the other hand, 9.8% of the 
patients reported an increase in severity from mild to moderate. Severe psoriasis 
developed into mild psoriasis in 7.1% of patients. In 8.0% and 7.8% of patients who 
reported a mild or moderate disease, respectively, disease activity stayed in the 
same category when they reached their adult life.
Treatm ent
Prescribed treatments in adult psoriasis were mainly topical corticosteroids, 
vitam in D analogues, UV-therapy and emollients. In childhood psoriasis, mainly 
emollients, topical corticosteroids, UV-therapy and coal tar were prescribed (Fig. 1). 
After stratification of the treatments into groups according to potency, the most 
potent treatment used in adult life was determined. The most potent treatment
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Table 4 Transition of severity of psoriasis from childhood to adulthood in 
childhood onset psoriasis (n= 681)*
Severity in childhood (%)
>■0 .t; o
? !
«
Clear Minimal Mild Moderate Severe Very
Clear 0.1 0.3 0.7 0.8 0.8 0.3
Minimal 0 1.8 3.4 5.2 3.2 1.8
Mild 0.1 4.8 8.0 13.8 7.1 3.4
Moderate 0.3 4.1 9.8 7.8 3.5 2.8
Severe 0 0.8 3.1 2.5 1.3 1.0
Very severe 0 0.4 0.4 0.7 0.4 0.7
r Numbers presented as percentages of patients
F igure 1 Treatments prescribed in adult and childhood psoriasis
I Childhood psoriasis (n=715) 
I Adult psoriasis (n =  1926)
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used was not different between COP and AOP (%2; p = 0.868) (Table 5). 
Of patients with COP, 43.3% was prescribed the same potency of treatment in 
childhood as in adulthood, whereas 51.7% was prescribed a more potent treatment 
in adulthood compared to childhood. Only 5.0% of COP patients received a less 
potent treatment in adulthood than in childhood. Overall, treatments used in 
adulthood were more potent than in childhood in COP (paired f-test; p < 0.001). 
A majority of patients (i.e. 50.9%) indicated that they were currently treated by a 
dermatologist. On the other hand, 570 (29.8%) respondents were not currently 
treated by any medical professional for their skin disease. These percentages 
were not different between COP and AOP (%2; p = 0.065). If patients had severe 
psoriasis (SAPASI > 10), they were more often under the care of a dermatologist 
for their skin disease than patients with a less severe form (%2; p < 0.001).
Table 5 Strongest treatment prescribed in adulthood
Total 
(%) 
(n =
I Childhood onset 
(COP) (%)
1909) (n = 711)
Adult onset 
(AOP) (%) 
(n = 1198)
X 2 test 
p - value
0.868
No treatment 0.4 0.6 0.3
Emollients 2.0 2.0 2.1
Topical 1st line therapy 51.3 51.2 51.4
Topical 2nd line therapy 17.7 18.4 17.2
Systemic treatment 19.1 18.4 19.4
Biologies 9.5 9.4 9.6
Delay in d iagnos is
The period between the first skin lesions and the final diagnosis was designated 
as the delay in diagnosis. In the study population questioned, the mean delay in 
diagnosis was 2.1 years (range 0 - 59 years). In COP, delay in diagnosis was 
longer (3.1 years) compared with AOP (1.5 years) (unpaired f-test; p < 0.001).
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Fam ilia l d is tr ib u tio n
A family history of psoriasis was noted in 1268 patients (67.3%). Affected 
first-degree family members were seen in 33.3%, affected second-degree family 
members in 41.0% and affected third-degree fam ily members in 22.9%. In 61.0% 
of patients in AOP, a positive family history of psoriasis was noted. In COP, this 
percentage was significantly higher (78.0%; %2; p < 0.001). See Table 6 for a 
subdivision in 1st, 2nd and 3rd degree family members affected.
Table 6 Familial distribution
Total
(%)
(n = 1883)
Childhood onset 
(COP) (%)
(n = 703)
Adult onset 
(AOP) (%) 
(n = 1180)
X2 test 
p - value
Family affected 67.3 78.0 61.0 < 0.001*
> one 1st degree member 33.3 39.9 29.5 < 0.001*
> one 2nd degree member 41.0 49.5 35.9 < 0.001*
> one 3rd degree member 22.9 30.3 18.6 < 0.001*
* Significant value
P rec ip ita ting  fac to rs
Psychological stress was regarded as the precipitating factor in 30.8% of cases, 
whereas an infection was only mentioned by 9.4% of patients. Injury to the skin 
and medication use as a precipitating factor were referred to by 6.4% and 4.6% of 
patients, respectively. Fifty-four percent could not recall a precipitating factor. No 
significant differences between COP and AOP were found for infections and injury 
to the skin as a precipitating factor (%2; p = 0.002 and p = 0.457, respectively). On 
the other hand, medication use and psychological stress were more often 
regarded as a precipitating factor in AOP (%2; p < 0.001 and p < 0.001).
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Discussion
Studies have been conducted to examine the frequency of onset of psoriasis in 
childhood. Our study shows that in 37.1% of respondents, the first signs of the 
skin disease occurred before the age of 18 years. This accords with earlier 
observations,14 which showed that 35 - 50% of all adult psoriasis patients already 
had psoriasis before the age of 20 years.
The two peaks in age of onset as found by Henseler and Christophers5 could not 
be found in our study. Our results show only one peak around the age of 15 - 19 
years (Fig. 2). This could be attributed to the fact that the mean age of respondents 
was 55.8 years, which, according to Henseler5, is the age of the second expected 
peak in age of onset.
F igure 2 Age of onset of psoriasis
0 10 20 30 40 50 60 70 80
Age of onset (years)
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Several studies Indicate that In children with psoriasis, BMI Is often too high as 
compared with WHO standards.911 Our study shows that COP does not seem to 
be an additional risk factor for a higher BMI In adult life.
In concordance with other studies1215, plaque psoriasis was the most frequent 
type of psoriasis seen In our study In both adults and children. Guttate psoriasis 
also often occurs In children; frequencies vary from 6.4% to 44%.12;13;17 In the 
current study, 33.9% of patients are reported to have had guttate psoriasis In their 
childhood. This study also confirms that guttate psoriasis In adults occurs more 
often In COP than In AOP. Additionally, the type of psoriasis seen In childhood 
often remains the same In adulthood. This counts for plaque psoriasis as well as 
guttate psoriasis (57.1% and 48.5%). This Is In contrast with the assumption In 
literature that guttate psoriasis resolves spontaneously or turns Into plaque 
psoriasis In later life.1,3“20 In the area of flexural, genital and perianal psoriasis not 
much research has been performed. Involvement of these areas was reported In 
2 - 44% of adult psoriatic patients.2- 1 In the present study, perianal Involvement 
was seen In 30% of patients, whereas genital areas were affected In 45.3%. In 
childhood, only a mere 1.4% and 3.5% of COP patients reported perianal or genital 
Involvement, respectively.
After diagnosing a child with psoriasis, the course of severity Is a frequently 
addressed subject by parents. There Is no consensus In published literature 
whether onset of psoriasis In childhood predicts a milder or more severe form of 
psoriasis.22 24 Our study Indicates that the course of severity will generally not get 
worse from childhood to adulthood. In addition, there Is no Indication that the 
course of COP Is worse than that of AOP.
Severity of psoriasis can also be determined by assessing the most potent 
treatment prescribed. In adulthood, there Is no significant difference In potency of 
treatments between COP and AOP. On average, the most potent treatment 
prescribed Increases with age In COP. This probably reflects the fact that 
physicians are more Inclined to treat children with less potent therapies. 
Diagnosis delay was significantly longer In COP than In AOP. As juvenile psoriasis 
sometimes has a different clinical appearance (nummular eczema-llke), often 
Itches and has a relatively low prevalence, general practitioners might miss the 
correct diagnosis.
In several studies, a higher percentage of familial distribution In COP has been 
reported.5;17;25 Others found no statistical correlation between positive or negative 
family history and age of onset.4 In the latter study, more COP patients had an 
affected 1st degree family member than the AOP patients. In the present study, a
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positive correlation between COP and a positive family history was found, as well 
as a correlation between COP and affected 1st degree family members.
The present findings on gender distribution are consistent with other research, 
which found that in childhood more women are affected with psoriasis than
men.4;15;17;25
A lim itation of this study is that several data were obtained retrospectively. 
Therefore, a recall bias may be present. Also, there could be a selection bias 
because the questionnaires were sent to members of the Dutch Psoriasis Society. 
Patients in whom psoriasis only occurred in childhood are possibly missed, 
because they might not be members of the Dutch Psoriasis Society in adulthood. 
Confounding due to a shorter follow-up duration in AOP could have occurred. 
Despite of these possible biases, this study has uncovered several important 
factors of childhood and adult onset psoriasis in a large group of patients.
The present study indicates that the diagnosis of psoriasis in childhood is delayed 
as compared with diagnosis in adulthood. Therefore, educational programs for 
general practitioners and paediatricians should address the difficulties in 
diagnosing childhood onset psoriasis.
The main conclusions can be summarized as follows: (i) a positive family history 
of psoriasis is more often seen in patients with childhood onset psoriasis; (ii) the 
development of guttate psoriasis and erythroderm ic psoriasis in adulthood is 
more frequent in childhood onset psoriasis; (iii) there are no differences in adult 
psoriatic patients with regard to severity of disease and frequency in the use of 
systemic treatments between childhood onset psoriasis and adult onset psoriasis; 
(iv) getting psoriasis in childhood does not seem to influence marital status as 
compared to adult onset psoriasis; (v) a strong correlation between childhood 
onset psoriasis and a higher BMI at adult age could not be found; (vi) type of 
psoriasis in childhood onset psoriasis remains the same from childhood to 
adulthood in a majority of patients. These conclusions can be helpful in daily 
practice when informing children with psoriasis and their parents.
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Abstract
Introduction
A study was conducted to explore epidemiology of childhood psoriasis In general 
practitioners (GPs) and dermatologlcal practice In the region of our academic 
medical centre. The treatments used by GPs and dermatologists In juvenile 
psoriasis were Investigated.
Methods
A questionnaire was sent to 229 GPs and 73 dermatologists. Questions were 
addressed about the prevalence of childhood psoriasis and treatments used In 
this disease.
Results
Seventy-three questionnaires were completed. The response rate was 17.0% for 
GPs and 46.6% for dermatologists. A lm ost one-third of all GPs have seen one or 
more patients with juvenile psoriasis underthe age of 11 years In their own patient 
population, In contrast to more than 80% of the dermatologists. Extrapolating the 
results Implied an estimated prevalence of childhood psoriasis of 0.17% In the 
overall Dutch population. Topical corticosteroids were used by 46.2% of GPs and 
by 91.2% of dermatologists. Vitamin D analogues were prescribed by GPs and 
dermatologists In 15.4% and 73.5%, respectively. Systemic medication for juvenile 
psoriasis was only used by 20.6% of dermatologists.
Conclusions
Calculated for the Dutch population, there should be approximately 27 500 children 
w ith psoriasis In The Netherlands are expected. Topical corticosteroids were the 
first-choice treatment In both GPs and dermatologists, whereas vitam in D 
analogues were used as a second-choice topical therapy. Systemic medication 
was only sparsely prescribed by dermatologists.
Epidem iology and treatments in childhood psoriasis
Introduction
Psoriasis is a chronic, inflammatory skin condition that affects about 2% of w orld ’s 
population. Onset in childhood is relatively common. Psoriasis accounts for 4% of 
dermatoses in children under 16 years of age in North America and Europe,1 but 
prevalence in various parts of the world may differ2. According to the literature, 35
- 50% of all adult psoriasis patients already had psoriasis before the age of 20 
years (Table 1).3-6 In contrast to these facts, however, the impression of the authors 
is that children w ith psoriasis are rarely seen in out-patient dermatology clinics in 
The Netherlands. According to the Continuous Morbidity Registration Nijmegen 
(CMR-N),7 in which, among other diseases, the prevalence of childhood psoriasis 
in a number of general practitioner practices is registered, the prevalence is still 
lower than can be expected based on published literature. These discrepancies 
raised the question as to what is the current situation in The Netherlands on 
prevalence of childhood psoriasis ingenerai practitioners (GPs) and dermatological 
practices. In addition, we wanted to investigate the actual daily practice of treating 
childhood psoriasis in GP and dermatologist practice.
Table 1 Onset of psoriasis under the age of 20
Onset < 20 years;
% of adults w ith psoriasis
Swanbeck3 1995 50%
Färber4 1974 35%
Braun-Falco5 1972 38.5%
Raychaudhuri6 1995 46.3%
The two major aims of the present pilot study were to explore epidemiology of 
childhood psoriasis in GP and dermatological practice and to obtain an overview 
of treatments used by GPs and dermatologists in children with psoriasis.
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Methods
A questionnaire was developed and sent to 229 GPs and 73 dermatologists in the 
region of our academic medical centre. The questionnaire was accompanied by 
an invitational letter explaining the purpose of the study. The first part of the 
questionnaire concerned the estimated prevalence of childhood psoriasis in the 
practice of GPs and dermatologists. In the second part, the treatments used in 
children with psoriasis were investigated. Questions were addressed about the 
number of children with psoriasis, age of children at diagnosis, exacerbating 
factors, familial components and treatments prescribed. Responses were 
gathered and data were analyzed. In the questionnaires, the number of affected 
children was requested by an estimation of number of patients according to four 
categories: no patients, one to five patients, six to 10 patients and more than 10 
patients.
Results
A total of 73 questionnaires were returned; 39 by GPs (response rate 17.0%) and 
34 by dermatologists (response rate 46.6%).
Of the 39 GPs, 30.8% (n = 12) has seen one or more patients with juvenile 
psoriasis under the age of 11 years in their own patient population. In the 
dermatologist practice, 82.4% (n = 28) of the dermatologists has one or more 
patients under the age of 11 years in their patient population. The number of 
patients seen in this age group is between one to five patients in the majority of 
dermatologist practices (i.e. 73.5%; n = 25). Further characteristics are depicted 
in Table 2.
From the results found in this study, the prevalence in the Dutch population can 
be calculated. After analyzing the results, this comes down to 0.92 children per 
GP under the age of 11 years with psoriasis and 2.26 children per GP from the 
age of 11 years with psoriasis. This results in a prevalence of 0.17% of childhood 
psoriasis in the overall Dutch population (8673 registered GPs [according to 
National Institute for Public Health and the Environment] and 16.4 million 
inhabitants in 2007 [according to Statistics Netherlands]). If the results are 
extrapolated across the Dutch population from the questionnaire presented, this 
implies a calculated prevalence of 0.37% and 1.09% for the age group of 0 - 10 
years (2 166 000 children) and 11 - 1 9  years (1 793 000 children), respectively.
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Table 2 Juvenile psoriasis divided per age category
GPs Dermatologists
No. of patients < 11 years > 11 years < 11 years > 11 years
0 27 13 6 1
1 - 5 12 24 25 16
6 - 10 0 2 3 9
> 10 0 0 0 23
GPs General practitioners
Age of onset was calculated per respondent (Figure 1). Most children were 16-19 
years old when their psoriasis was diagnosed. This was the same for both 
populations (GP practice and dermatologist practice).
According to GPs, psoriasis was more often diagnosed In boys than In girls 
(61.9% versus 38.1%). By way of contrast, dermatologists reported a slightly 
higher percentage In girls (I.e. 57.3% versus 42.7%).
F igure 1 Age of onset of juvenile psoriasis
No. per general practitioner 
No. per dermatologist
0 -4 y e a rs  5 - 1 0 years 1 1 -1 5  years 1 6 -1 9  years
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GPs and dermatologists reported virtually the same frequency of familial 
distribution among children with psoriasis: 48.4 and 52.1%, respectively. 
Questions were asked about the correlation between infections and the onset of 
psoriasis. Eighty-one percent of GPs never found a correlation between the first 
appearance of skin lesions and an infection compared with 29.4% of derma­
tologists. Of dermatologists, 50% stated that in approximately 30% of their patients 
w ith juvenile psoriasis an infection played a role in the onset of the disease.
Nail deformities were only seen in 5.3 to 7.4% of patients. There was no difference 
in frequency between the groups seen by dermatologists or GPs.
The frequency of joint pain was also assessed. A lm ost 12% and 12.8% of GPs 
and dermatologists, respectively, have seen joint pain in one or more of their 
patients. Of the GPs who recorded joint pain, it was seen in 7.2% of patients. Only 
1.2% of the children in the derm atologists’ population mentioned joint pain. 
Prescribed treatments for psoriasis are shown in Table 3. A large number (i.e. 
46.2%) of GPs prescribed topical corticosteroids for juvenile psoriasis. Bland 
emollients were also used by 33.3% of GPs. Vitamin D analogues were only used 
by 15.4% of GPs. Dithranol (n = 1), coal tar shampoo (n = 1) and homeopathy 
(n = 3) were occasionally mentioned by GPs as a treatment option for childhood 
psoriasis.
Table 3 T rea tm en ts  used fo r ch ild h ood  p sorias is
Treatment % of dermatologists % of GPs
Corticosteroids 91.2 46.2
Vitamin D analogues 73.5 15.4
Phototherapy 64.7 0
Dithranol 20.6 2.6
Neotigason 8.8 0
Methotrexate 8.8 0
Excimer laser 2.9 0
Coal tar ointment at night 11.8 0
Fumarie acid 2.9 0
Homeopathy 0 7.7
Emollients 8.8 33.3
GPs General practitioners
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The first-choice treatment among dermatologists was topical corticosteroids, 
applied by 91.2% of dermatologists, followed by vitam in D analogues (73.5%). A 
relatively high percentage (64.7%) of dermatologists also prescribed phototherapy 
for their patients. In contrast, systemic medication was only prescribed by 20.6% 
of the dermatologists.
CM
C\iDiscussion
Reports on the age of onset of psoriasis vary among studies (Table 1). A large 
cohort study among 11 366 patients in Sweden showed that 30% of patients was 
youngerthan 15years at the onset of their psoriasis and 20% had an onset between 
the age of 15 and 19 years.3 Färber and Nall found that 10% of their whole examined 
population had an onset before the age of 10 years and 35% before the age of 20 
years.4 Others demonstrate an onset before the age of 16 years in 45% of patients.8 
Braun-Falco et al5 and Raychaudhuri and Goss6 have shown an onset before the 
age of 20 years in 38.5% and 46.3% of patients, respectively. Based on these 
articles and the assumption that 2% of the Dutch adult population has psoriasis, 
there should be approximately 140 000 children in The Netherlands with juvenile 
psoriasis. Our study shows a prevalence of 0.37% in the age group from 0 to 10 
years old and a prevalence of 1.09% in the age group from 11 to 19 years old. When 
this is calculated for the Dutch population, there are approximately 27 500 children 
with psoriasis, which is substantially lower than numbers from the literature. One 
possibility is that literature published in the past overestimates the onset of psoriasis 
in childhood. However, it is also possible that our study underestimates the actual 
prevalence of children with psoriasis because this number only reflects the patients 
who are currently under the control of a GP. On the other hand, in a more recent 
study in the United Kingdom a prevalence of 0.55% was found of juvenile psoriasis 
in the age group 0 - 9 years.9 In the same way, a prevalence of 1.37% was found in 
the age group 10 - 1 9  years old (Table 4), which is consistent with our findings.
As Table 2 indicates, young children w ith psoriasis (i.e. < 11 years) are more often 
seen by a dermatologist than a GP. In our own experience, younger children are 
more frequently referred to our academic centre for diagnosis, whereas older 
children are more often referred for the treatment of their already-diagnosed 
psoriasis. This could be caused by the sometimes different appearance of juvenile 
psoriasis. Also, because this disease has a low prevalence, GPs often do not 
consider or are uncertain about this diagnosis.
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Table 4 Prevalence of childhood psoriasis by age group
0 - 9 years 10 -19  years
Gelfand9 0.55% 1.37%
RUNMC 0.37% 1.09%
RUNMC Radboud University Nijmegen Medical Centre
As in adults, genetic predisposition Is also found In children. In the present study, 
a familial distribution with an average of 50.3% was described. Slgure and Rubins 
found evidence of psoriasis In family members In 26% of 252 children with 
psoriasis.10 Others report higher percentages up to 71%.6:11:12 
Several trigger factors In the development of psoriasis have been Identified. Most 
Important are stress, medication (e.g. antlmalarlals and withdrawal of oral cortico­
steroids) and trauma.13;14 Beta haemolytlc streptococcal pharyngitis or, less 
frequently, perianal streptococcal dermatitis can provoke guttate psoriasis.1517 
Our study demonstrates that only a few GPs have linked the occurrence of 
psoriasis with a concurrent Infection. Am ongst dermatologists this share Is bigger, 
possibly because dermatologists more often refer to this topic In their 
anamnesis.
As our study shows, nail psoriasis Is mentioned by GPs and dermatologists In 5.3
- 7.4% of children w ith psoriasis. Accordingly, this has also been observed In 
other studies, In which 7 - 40% of patients under the age of 18 years had nail 
Involvement. In these studies, the most frequently seen abnormality was 
pitting.8;12;18-22
Approximately 12% of GPs and dermatologists report that they have seen one or 
more juvenile patients with psoriasis and joint pain. The estimate of the prevalence 
of psoriatic arthritis among patients with psoriasis has varied from 6 to 39%.23 
Estimates of prevalence of psoriatic arthritis in children with psoriasis were not 
found in the literature published.
As expected, the most common treatments used were corticosteroids and vitamin 
D analogues. Of both treatments, topical corticosteroids are prescribed more 
often, even though vitam in D analogues are equally efficient and have fewer side 
effects than topical corticosteroids.24 35 Another noteworthy fact is that systemic 
medication is sparsely prescribed, even by dermatologists. One can speculate 
whether this is due to milder disease in children, or maybe dermatologists have
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reservations about treating children with systemic antipsoriatic medication. 
Further research is needed to clarify this matter.
Despite the lim itations of this retrospective analysis (e.g. error in recall of 
information), the results found in this pilot study point out that there is a compelling 
need for more research on childhood psoriasis. In addition, guidelines for 
treatment are needed. It should also be taken into account that children will have 
to live longer with their disease than adults. Because of this, cumulative toxicity of 
treatments given is a major concern and long-term safety is an important issue.
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Abstract
Background
The first manifestations of psoriasis begin in childhood in more than one-third of 
patients. However, epidemiological data of juvenile psoriasis are lacking. 
Objective
To compare Dutch (NL group) and Singaporean (SG group) children with psoriasis 
w ith the aim to study the characteristics of juvenile psoriasis and to highlight 
sim ilarities and differences between these different ethnic groups.
Methods
Data were collected from 207 patients younger than 18 years of age diagnosed 
with psoriasis from the Radboud University Nijmegen Medical Centre, Nijmegen, 
The Netherlands and the National Skin Centre, Singapore.
Results
A striking difference in familial distribution was found, with more Dutch children 
having an affected family member (73.3% vs. 13.6%). Presence of itch and 
triggering factors were more common among Dutch children (80% vs. 14.2% and 
33.3% vs. 7.4%, respectively). However, both groups shared similar triggering 
factors like stress and infections. The mean age at presentation was 11.3 years in 
the NL group and 14.1 years in the SG group. The gender ratios in both groups 
were almost sim ilar (NL group, men : women; 1 : 1.1; SG group, men : women;
1 : 1.4). Plaque psoriasis was the most common type in both cohorts while guttate 
and pustular psoriasis were rare. In both groups, the head, followed by the limbs, 
was the most common site involved. Sim ilar proportion of children had nail 
involvement and psoriatic arthritis was rare in both countries.
Conclusion
The disparity in familial distribution may point to genetic differences between the 
two groups. Further studies to evaluate this difference in familial distribution may 
contribute to the understanding of the pathogenesis of psoriasis.
Juvenile psoriasis and ethnicity
Introduction
Psoriasis is quite common in childhood with 31 - 45% of all adult psoriasis patients 
manifesting signs before the age of 20 years.1-  We present a comparative study 
between Dutch and Singaporean children with psoriasis. Our aim was to study 
the characteristics and epidemiology of juvenile psoriasis and to highlight the 
sim ilarities and differences between European and Asian patients.
Materials and methods
Data were collected from patients younger than 18 years of age diagnosed with 
psoriasis in the two countries. In The Netherlands (NL group), all juvenile psoriasis 
patients presenting at the dermatology outpatient clinic at the Radboud University 
Nijmegen Medical Centre between 1 August 2008 and 31 December 2009, were 
included. Data were obtained directly from the patients for the purpose of this 
study. For Singaporean children with psoriasis (SG group), data were obtained 
from the electronic case files at the National Skin Centre from 1 January 2008 to 
31 May 2009. The following characteristics were looked into: age at presentation, 
gender, age of onset, ethnicity, family history, triggering factors, presence of itch, 
type of psoriasis, sites of involvement, comorbidities and treatment modalities.
Results
A total of 207 patients were included in this study (NL group 45; SG group 162). 
The mean age at presentation for Dutch and Singaporean children was 11.3 years 
(range 4.3 -17.9) and 14.1 years respectively (range 1.3 -17.9). The male to female 
ratio was 1 : 1.1 (NL group) and 1 : 1.4 (SG group). The mean age of onset for 
Dutch patients was 7.6 years (range 0.5 -14.8) and 10.3 years (range 0.4 -17.1) for 
Singaporeans. The SG group consisted of Han Chinese (43.2%), Malays (30.9%), 
Indians (19.1%) and other ancestries (6.8%) (Table 1). The NL group mainly 
consisted of Caucasians (82.2%) (other ancestries 17.7%). Eighty-two percent of 
Dutch patients exhibited skin types II and III, while all Singaporean patients had 
skin type III to V.
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Table 1 Comparison between Dutch patients and Singaporean patients
Characteristics NL group SG group
Number of patients 45 162
Men : Women 1 : 1.1 1 : 1.4
Mean age at presentation (range) 11.3 years (4.3 - 17.9) 14.1 years (1.3 - 17.9)
Mean age of onset (range) 7.6 years (0.5 - 14.8) 10.3 years (0.4 - 17.1)
Ancestry (%)
Caucasian 82.2 0
Han Chinese 0 43.2
Malay 0 30.9
Indian 0 19.1
Other 17.8 6.8
Positive fam ily h istory (%)
Total group 73.3 13.6
Caucasian 83.8 -
Han Chinese - 13.4
Malay - 14
Indian - 19.4
Other ancestries 25 -
Triggering factors (%)
Total group 33.3 7.4
Caucasian 37.8 -
Han Chinese - 4.5
Malay - 10.0
Indian - 12.9
Other ancestries 12.5 -
Presence of itch (%)
Total group 80.0 14.2
Caucasian 83.8 -
Han Chinese - 16.4
Malay - 14
Indian - 12.9
Other ancestries 62.5 -
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Table 1 C ontinued
Characteristics NL group SG group
Type of psoriasis (%)
Plaque 88.9 88.3
Guttate 2.2 4.3
Pustular 6.7 2.5
Sites involved (%)
Head 88.9 75.9
Limbs 86.7 47.5
Intertriginous sites 24.4 5.6
Facial 24.4 27.3
Nail involvement (%) 22.2 35.8
Arthritis (%) 2.2 1.2
NL g roup Dutch patients 
SG g roup Singaporean patients
A striking difference between the two populations was that only 13.6% of 
Singaporeans had a first- or second-degree relative affected by psoriasis compared 
to 73.3% of Dutch children (Caucasians 83.8% and other ancestries 25%). Within 
the Singaporean cohort, 13.4% of Han Chinese, 14% of Malays and 19.4% of 
Indians had a positive family history. Among patients who reported triggering 
factors, stress was the most common cause in both groups (NL group 66.7%; SG 
group 50%), followed by infections (NL group 20%; SG group 25%). However, a 
greater proportion (33.3%) of Dutch patients (Caucasians 37.8%; Other ancestries 
12.5%) reported triggering factors compared to Singaporean patients (total group 
of Singaporean patients: 7.4%; Han Chinese 4.5%; Malays 10%; Indians 12.9%). 
Itch was experienced by 80% of Dutch children (Caucasians 83.8%; other 
ancestries 62.5%), but only by 14.2% of Singaporean children (Han Chinese 
16.4%; Malays 14%; Indians 12.9%). In both groups, plaque psoriasis was the 
most common type of psoriasis (NL group 88.9%, SG group 88.3%), while few 
children presented with guttate psoriasis (NL group 2.2%; SG group 4.3%). 
Pustular psoriasis accounted for 6.7% of all cases among Dutch children and 
2.5% among Singaporean children. The head was the most common site involved
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in both groups (NL group 88.9%; SG group 75.9%), followed by the limbs (NL 
group 86.7%; SG group 47.5%). Intertriginous sites were Involved In 24.4% of 
Dutch children compared to 5.6% of Singaporean children. Sim ilar proportions of 
children had facial (NL group 24.4%; SG group 27.3%) and nail Involvement (NL 
group 22.2%; SG group 35.8%), with pitting being the most common nail sign. 
Arthritis was rare In both groups (NL group 2.2%; SG group 1.2%) (Table 1).
Discussion
The most outstanding result of this study was the disparity In familial distribution 
between the two groups. It Is known that 4.5% - 91% of psoriatic children have a 
family history of psoriasis.3 9 The numbers found In the Dutch cohort (73.3%) 
compared favourably with data from Australia3 (71%) and Faroe Islands7 (91%), 
which have a predominantly Caucasian population. In contrast, data from the SG 
group (13.6%) are similar to data from Korea8 (13.3%) and lndla5;9 (4.5% to 9.8%). 
A Chinese survey revealed a positive family history of 34.4%.5 The disparity In 
familial distribution between Caucasian and predominantly Han Chinese patients 
could be due to genetic differences. It has been demonstrated that IL23R 
polymorphisms could not be Identified In the Han Chinese population with 
ankylosing spondylitis (AS), whereas IL23R polymorphisms were present In the 
Caucasian population.10 As IL23R polymorphisms have also been Identified In 
psoriasis as a common susceptibility factor, this same mechanism could explain 
the difference In familial distribution between our two populations.11 
The mean age of onset of our patients was sim ilar to recent published reports.4:5 
Marginally more women were found In both groups, which was also noted In other 
studies.3;5;12 Although more Dutch patients recalled triggering factors, both our 
European and Aslan children shared sim ilar triggers of stress and Infections. In 
India and Kuwait, Itch was a frequent symptom, reported by 87.1% and 72% of 
patients, respectively.'613 The vast majority of our Dutch patients experienced Itch, 
unlike Singaporean children.
In concordance with published reports,3;5;5;13 plaque psoriasis was the most 
common type of psoriasis In both cohorts. A marked difference between our 
series and others was the number of cases of guttate psoriasis (NL group 2.2%; 
SG group 4.3%). This Is lower than figures from previous reports, which ranged 
from 6.4% to 44%.3:14 Pustular psoriasis Is considered to be rare In children,3:5 a 
finding noted In both groups. In contrast to studies from China and India5 6, where
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the most frequent site of involvement was the extremities, the head was most 
commonly involved in both our cohorts, followed by the limbs. Facial psoriasis 
was common in both groups, agreeing with earlier observations that facial 
involvement in juvenile psoriasis is prominent.3:15 Intertriginous areas and genitals 
are commonly affected in children.15117 A quarter of Dutch patients had involvement 
of their intertriginous areas, unlike Singaporean children (5.6%). The proportion of 
children with nail involvement was sim ilar to that reported by Nanda et al.9 Our 
series also confirms that psoriatic arthritis is very rare in children.4;15;17 
There were more Singaporeans in this study as the National Skin Centre is the 
main dermatology referral centre in Singapore, which has a population of 4.8 
million. The Department of Dermatology of the Radboud University Nijmegen 
Medical Centre is an academic centre, serving a population of approximately 2 
million. Recall bias due to the different types of data sources between the two 
groups may lead to differences in the more subjective and patient reported 
outcomes like itch and affected fam ily members. In contrast, the more objective 
and clinically standardized outcomes like type and location of psoriasis were 
similar.
In summary, plaque psoriasis was the most common type in both European and 
Asian children while guttate psoriasis was rare. The groups shared sim ilar gender 
ratios, sites of involvement and proportions with facial and nail involvement. 
Arthritis was rare in both groups. More European children reported positive family 
history, triggering factors and itch. The most noteworthy finding is the disparity in 
familial distribution between European and Asian children, which may to be due 
to genetic differences. Further genetic studies may contribute to the understanding 
of the pathogenesis of psoriasis.
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Abstract
Background
Evidence-based recommendations for therapeutic decision making in childhood 
psoriasis are lacking.
Objectives
We sought to systematically review all available literature concerning treatment 
efficacy and safety in childhood psoriasis and to propose a recommendation for 
topical and systemic treatment of childhood psoriasis.
Methods
Databases searched were Pubmed, EMBASE and the Cochrane Controlled 
Clinical Trial Register. All studies reporting on efficacy and safety of all treatment 
options in childhood psoriasis were obtained and a level of evidence was 
determined.
Results
Literature search revealed 2649 studies, of which 64 studies met the inclusion 
criteria. The majority of topical and systemic therapies given in childhood psoriasis 
are efficacious. Short-term side effects were usually mild; long-term side effects 
were not described.
Limitations
Most conclusions formulated are not based on randomized controlled trials. 
Conclusions
A rough summary of the proposed algorithm is as follows: first, calcipotriol with or 
without topical corticosteroids, followed by dithranol. Methotrexate is considered 
to be the systemic treatment of choice.
Treatments for childhood psoriasis
Introduction
Psoriasis is a chronic, inflammatory condition of the skin that affects about 2% of 
the general population. Onset in childhood is relatively common. Therefore, knowledge 
about therapeutic options in childhood psoriasis is important. Psoriasis accounts 
for 4% of dermatoses in children younger than 16 years in North America and 
Europe1, but prevalence in various parts of the world may differ2.
For treatment of patients with psoriasis, a spectrum of topical treatments, photo- 
(chemo)therapy, conventional systemic treatments and biologies is available. 
Treatment of childhood psoriasis has been described in a few reviews.3 5 In these 
publications, the literature was not systematically reviewed and recommendations 
were not based on the principles of evidence-based medicine. To our knowledge, 
evidence-based guidelines describing the preferential order of treatments used 
for childhood psoriasis are not available.
The aim of this paperwasto systematically reviewall available literature concerning 
efficacy and safety of all treatment options for childhood psoriasis. On this basis, 
a recommendation for the topical and systemic treatment of childhood psoriasis 
is made.
Methods
Three bibliographic databases were searched from January 1980 to September 
2008: Pubmed, EMBASE and the Cochrane Controlled Clinical Trial Register. 
“Psoriasis”, “child”, and “treatment” were used as main keywords, including all 
possible synonyms and antipsoriatic treatments (generic names and brand 
names). Languages were limited to English, German and Dutch. Full details on 
the search strategy are available from the corresponding author on request. 
Because the available literature about childhood psoriasis is limited, all available 
literature was reviewed, including case reports, case series, retrospective studies, 
open-label trials and randomized controlled trials (RCTs) concerning all different 
types of childhood psoriasis (e.g. plaque, guttate, pustular). Studies reporting on 
efficacy of all different treatment options for childhood psoriasis (age < 18 years) 
were included. Description of an outcome measure was mandatory. Outcome 
measures included Psoriasis Area and Severity Index (PASI); Physician Global 
Assessment (PGA); total severity score for erythema, scaling and thickness; and 
more subjective parameters such as percentage of clearance. Excluded were
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studies describing antipsoriatic combination therapies (except for a combination 
with low- to moderate-potency topical corticosteroids) and studies concerning 
psoriatic arthritis. If the treatment regimen was unclear, the study was not included. 
Articles on both children and adults were only included if their data were reported 
separately. Studies on treatment modalities that were only described once as a 
monotherapy in the literature were also excluded. The bibliographies of all articles 
identified were checked for additional relevant articles that were not identified in 
the database search. After the initial search was performed, abstracts were 
screened for inclusion and exclusion independently by two reviewers (M.E.A.d.J. 
and M.M.B.S.). Of the 2649 studies found, 2533 were excluded because the 
abstracts showed that the studies were not eligible for inclusion. Subsequently, 
full text of the remaining articles was obtained. Data on study characteristics 
(both methodological and clinical) were independently extracted from each full 
text article by the same two reviewers (M.E.A.d.J. and M.M.B.S.) and recorded on 
a predesigned data extraction form. Finally, 64 articles were included in this 
review. Study characteristics included study design, study population, number of 
participants, duration of treatment, primary outcome, blinding, side effects, 
duration of remission and level of evidence (LOE). The LOEs were determined on 
the Oxford Centre for Evidence-based Medicine Levels of Evidence (Table 1).5
Table 1 Leve l of e v idence  (LOE)
1a Systematic review of RCTs
1b Individual RCT
2a Systematic review of cohort studies
2b Individual cohort study (including low quality RCT)
3a Systematic review of case-control studies
3b Individual case-control study
4 Case series
5 Case reports, expert opinion
Adapted from “Oxford Centre for Evidence-based Medicine Levels of Evidence” version 
May 20016
RCT Randomized controlled trial
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All case reports were considered to be equal to an expert opinion In the LOE. 
The conclusions are described In grades of recommendation (Ato D) (Table 2), 
which are based on the LOE. In addition to the grade of recommendation, the 
numbers of patients treated were cited. In addition, a classification was made by 
the authors to match the different outcome measures. Clearance was defined as 
more than 90% Improvement of the outcome parameters, whereas marked, 
moderate, slight, and poor Improvement were defined as 70 to 90%, 50 to 70%, 
30 to 50%, and less than 30% Improvement of the outcome parameters, 
respectively, compared with baseline. Initially, a subdivision In age categories 
was aimed for, unfortunately, this proved Impossible due to lack of age specification 
In the original articles. Differences among reviewers were resolved by discussion 
or by consulting a third Investigator.
Table 2 Grades of recommendation
A Studies with consistent LOE 1a and/or 1b (see Table 1)
B Studies with consistent LOE 2a, 2b, 3a, or 3b; or extrapolations from 
studies with LOE 1a or 1b
C Studies with LOE 4 or extrapolations from studies with LOE 2a, 2b, 3a, 
or 3b.
D Studies with LOE 5 or troublingly inconsistent or inconclusive studies 
of any level
Adapted from “Oxford Centre for Evidence-based Medicine Levels of Evidence” version 
May 20016
LOE Level of evidence
Results
In the results, all 116 full text articles are presented, as well as the reasons for exclusion 
of 52 articles. The details on the 64 studies Included are summarized In Table 3.
Topical corticosteroids
Literature research revealed 11 studies.717 Eight studies were excluded; two 
because there was no clear diagnosis of psoriasis7 8, one because of a vague 
description of treatment strategy9, three because of the lack of an Identified
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outcome measure1012, one because of a concomitant HIV infection15 and one 
because of the usage of an antipsoriatic combination therapy13.
Herz et al15 (LOE 4) published an open-label study on halobetasol cream 0.05%. 
In 72.7% of patients, lesions healed after two weeks of treatment.
A RCT performed by Kimball et al14 (LOE 4) showed a treatment success in two of 
eight treated patients after two weeks of treatment with clobetasol propionate 
emulsion formulation 0.05%. Noteworthy is that these data come from a subgroup 
analysis with a control group of only one patient. Because of this, and the low 
number of children included in this study, the level of evidence was down-graded 
to level 4.
One case report (LOE 5) described the use of hydrocortisone 1% ointment in a 
two-year-old child with pustular psoriasis17; clearance was achieved with cortico­
steroid application.
In two of the included studies, concerning halobetasol cream 0.05% and 
clobetasol propionate emulsion 0.05%, adverse events were mentioned. Mild skin 
atrophy, erythema and depigmentation were described after a treatment period 
of two weeks.1415 Burning at the application site was also mentioned as a side 
effect.14 Unfortunately, adrenal axis testing was not performed in these studies.
Conclusion
Grade C
Number of patients treated with topical corticosteroids: 20 
Halobetasol cream 0.05% and clobetasol propionate emulsion 0.05% seem to be 
efficacious treatments in childhood plaque psoriasis. Reported side effects were 
relatively mild in the treatment period of two weeks.
Vitamin D analogues
Ten publications on vitamin D treatment (eight calcipotriol and two calcitriol) in 
children with psoriasis were identified and assessed by data extraction forms.18 27 
One case report was excluded because of an unclear diagnosis.27
Oranje et al18 (LOE 1b) performed a randomized double-blind study in 77 juvenile 
patients. Calcipotriol (50 jL/g/g) was applied twice daily for eight weeks. The 
investigators reported a decrease in PASI score of 52% in the vitamin D group (n 
= 43) and 37.1% in the placebo group (n = 34). This difference was not statistically
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significant. However, reduction of the PGA at week eight and differences in 
morphology were statistically significant in favor of the active treatment group. 
Several other studies showed a positive effect of calcipotriol treatment on psoriatic 
lesions with an estimated outcome measure of clearance or marked improvement 
in at least 65% of cases.2125
Calcitriol ointment (3 jL/g/g) was applied in a randomized double-blind study19 
(LOE 2b), showing a residual mild erythema in all 10 patients. Perez et al20 
performed a study with calcitriol of which the first part was placebo controlled 
(LOE 2b) and the second part was open label (LOE 4). The same four patients 
with plaque psoriasis participated in both studies. In the first part of the study, 
total severity score (range 0 - 9) was reduced from 6.0 to 2.5 in the active treatment 
group; in the placebo group the score decrease from 6.0 to 5.8. In the second 
part, a mean PASI reduction of 94% was seen after 18 months of treatment.
Irritant reactions were seen in four of the calcipotriol studies18'21'23'25; moderate 
itching was seen in two studies22 23. In total, 8 of 98 participants from three studies 
in which dropout was described ceased treatment because of side effects. No 
adverse events were reported in two studies.19'28 The two remaining studies did 
not mention side effects.24'25
Conclusion
Grade A
Number of patients treated with calcipotriol: 155
Calcipotriol is an effective, reasonably well tolerated treatment option for childhood 
plaque psoriasis.
Grade B
Number of patients treated with calcitriol: 18
Calcitriol seems to be an effective treatment for childhood psoriasis with mild side 
effects.
Calcineurin inhibitors
Six studies were identified by literature search29 34; one was excluded because 
they used an antipsoriatic combination therapy34. Two studies were classified as 
LOE 429' 30 and three as LOE 531-33; all described calcineurin inhibitor use in 
psoriasis facialis and inversa (including anogenital psoriasis).
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In two non-randomized clinical trials treatment of facial and flexural psoriasis with 
tacrolimus 0.1% was evaluated.29 30 All patients showed clearance after a treatment 
period varying from 2 to 30 days. Tacrolimus 0.1% was also used In one case 
report.33 The facial psoriasis cleared totally.
The two remaining studies were case reports on the use of pimecrolimus cream
1.0%.31,32 In both cases total remission was achieved.
Pruritus was noted as an adverse event In one tacrolimus study.29 One patient 
discontinued the study because of this side effect. In two studies, calcineurin 
Inhibitors (tacrolimus and pimecrolimus) were well tolerated.30,32 The other studies 
did not describe adverse events.31,33
Conclusion
Grade C
Number of patients treated with tacrolimus: 20
Tacrolimus 0.1% seems an effective and safe therapeutic option for short-term treatment 
of facial and Intertriginous childhood psoriasis. Long-term safety was not described. 
No conclusion could be drawn for the use of pimecrolimus In childhood psoriasis 
because of a small number of patients.
Dithranol (anthralin)
Literature search revealed four studies describing dlthranol treatment In 
children.35 38 One was excluded because there was no outcome measure stated.38 
Two studies were classified as LOE 435,35; one was classified as LOE 537.
In one study short-contact dlthranol treatment In 58 patients was reviewed retro­
spectively.35 Of patients, 81% attained remission after a median treatment duration 
of two months. Guerrier and Porter35 performed a multicentre open-label study In 
which they applied dlthranol cream 0.1%. In all, 34 patients completed the study; 
mean percentage of clinical Improvement (± SEM) was 64 (± 11) In centre 1 (n = 11) 
and 77 (± 4) In centre 2 (n = 23) after six weeks of treatment. A case report 
demonstrated a marked Improvement of psoriatic lesions In a girl given the 
diagnosis of plaque psoriasis.37 Dlthranol was appi led In relatively low concentration 
(0.016% - 0.0625%) for three months.
Overall, total remission was found In 47 of 58 patients35 and marked Improvement 
In 35 of 42 patients35,37.
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Mild transient skin irritation (including burning sensation) and staining were the 
most frequently reported adverse events.35'35 In the case report of Schubert et 
al37, no adverse effects were reported. In summary, 4% of all patients described 
ceased treatment because of side effects.
Conclusion
Grade C
Number of patients treated with dithranol: 100
Dithranol is an effective treatment in childhood psoriasis with a good margin of 
safety for short-term use.
Phototherapy
Of the 13 studies identified, five studies described treatment of childhood guttate 
and plaque psoriasis with narrowband (NB)-ultraviolet (UV) B radiation.39 43 Pho­
tochemotherapy (psoralen plus UVA radiation (PUVA)) was the treatment examined 
in two case reports44'45 and one case series45. Five studies were excluded47 51: 
grounds for exclusion were systemic combination therapy in three cases4749, 
unclear diagnosis in one case50 and unclear treatment regimen in another case51. 
All studies included were classified as LOE 4, except for two case reports which 
were classified as LOE 5.44 45
Two open-label studies were performed. Jain et al40 examined NB-UVB treatment 
for 12 weeks. PASI 90 was achieved in 60% of patients. In all, 10% had less than 
50% improvement. It needs to be mentioned that all patients had skin type IV. Tay 
et al43 also studied NB-UVB treatment. After a mean treatment of 11.9 weeks, 
clearance was reached in all patients.
Three retrospective case reviews concerning NB-UVB were found. The most recent 
study from 2006 reviewed 35 cases41, which all had skin type V. Clearance or minimal 
residual disease was found in 63%, 9% had a poor response, and 28% of patient 
records could not be retrieved. Pasic et al42 obtained records from 20 patients. 
PASI 90 was reached in 45% and 15% showed less than 50% improvement. 
al-Fouzan and Nanda39 found a marked improvement in 88% of the 25 patients 
treated.
Of the case reports and case series, one used PUVA in plaque psoriasis44, one 
used suit-PUVA in guttate psoriasis45 and one used PUVA in erythema annulare 
centrifugum-type psoriasis45. In the former, lesions cleared after 18 treatments. In 
the second one, a marked improvement was seen after four weeks. The latter
79
Chapter 3.1
showed clearance of lesions In two children after 36 days, In which 15 to 21 
treatments were given.
In two studies erythema was reported In 10 to 30% of Included patients.40'41 One 
study mentioned anxiety as adverse event In 6.75% of treated children.41 In three 
studies39'42'43, 55 patients In all, NB-UVB was well tolerated. The two patients who 
received PUVA therapy In the case series did not have any side effects.45 The two 
case reports on PUVA treatmentdld not mention adverse events.44 45
Conclusion
Grade C
Number of patients treated with NB-UVB: 110
NB-UVB shows good results In the treatment of plaque and guttate psoriasis In 
childhood and has comparatively mild side effects for the treatment duration 
studied.
As only four patients were treated with PUVA, a solid conclusion about the use of 
PUVA could not be drawn.
Antibiotics
Literature search revealed nine studies In which childhood psoriasis was treated 
with antibiotics.52 50 Four were excluded because of various reasons: In one case 
report the treatment regimen was unclear57 and three studies did not describe a 
clear outcome measure58 50.
In one study thlamphenlcol was used (LOE 4).52 The two patients Included 
received thlamphenlcol 20 mg/kg/d; nevertheless, In both cases there was less 
than 50% clearance of lesions.
The four patients In the case serles53 (LOE 4) were all treated with erythromycin 50 
mg/kg/d for two weeks; In all patients the psoriasis lesions disappeared 
completely. In the case report54 (LOE 5), a patient with guttate psoriasis was 
treated with amoxlclllln/clavulanlc acid 50 mg/kg/d, which cleared all lesions after 
20 days.
Rosenberg et al55 performed an open-label trial (LOE 4) with both adults and 
children. Four juvenile patients were treated with penicillin or erythromycin for 10 
to 14 days; for the last five days rifampin was added to both treatments. All patients 
responded very well to the treatment; three had a good response and one had an 
excellent response.
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The only placebo-controlled study55 (LOE 4) concerning the use of antibiotics In 
childhood psoriasis was performed In just three children. Group A received oral 
penicillin V or oral erythromycin (250 mg) four times a day for 14 days and a 
placebo twice a day for the last five days of the 14 days. Group B received oral 
penicillin V or oral erythromycin (250 mg) four times a day for 14 days and oral 
rifampin (300 mg) twice a day for the last five days of the 14 days. One child was 
randomized In group A and two were randomized In group B; In both groups no 
clinical change was seen. As only three children were treated In this trial, the LOE 
was level 4.
Gastrointestinal disturbance was mentioned as a side effect In the thlamphenlcol 
study.52 The remaining studies did not describe side effects.53 55
Conclusion
Grade C
Number of patients treated with antibiotics: 14
The efficacy of the use of antibiotics In childhood guttate psoriasis remains 
controversial.
Retinoids
In contrast to other treatment options, numerous studies regarding retinoid use In 
children with psoriasis were found. In all, 21 studies were Identified45'49'50'52'5177, 
but five studies were excluded because of an unclear outcome measure45'5770, 
nine because they used systemic antipsoriatic combination therapies49'50'52 71“75 
and one case report because there was no clear diagnosis of psoriasis77. 
Therefore, six studies remained: four studies were classified as LOE 451'53 55; two 
were classified as LOE 552'55.
In 1988 a retrospective review of 10 cases was performed51 in which etretinate 
was used at an initial dose of 1 mg/kg/d, with a treatment duration varying from 
three weeks to more than 12 months. All patients with pustular psoriasis (n = 5) 
achieved complete clearance of lesions; in contrast, the erythrodermic psoriasis 
subgroup (n = 5) showed a complete clearance of lesions in only two and an 
improvement in the remaining three cases. Etretinate was also used in two case 
reports52 55, one case series53 and one open-label trial54. In one case report52 and 
one case series53 1.0 to 1.25 mg/kg/d was administered to patients with pustular 
psoriasis. All six patients had significant regression of erythroderma or even
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clearance. In the open-label study54, three patients with psoriasis erythroderma 
were treated with etretinate In a dosage ranging from 0.5 to 0.9 mg/kg/d. After 
four to five months of treatment, they all had complete clearance of erythema and 
scaling. Etretinate was used as a treatment for plaque psoriasis In two children.55 
It was administered at a dose of 25 mg/d for four to six weeks; after that, there was 
a dosage decrease to the maintenance dose of 12.5 mg/d. After 13 to 17 months, 
both patients had an excellent response. Only one case report described an 
excellent effect of 0.5 mg/kg/d acitretin In a child with erythrodermlc psoriasis.55 
Complete remission was achieved after three months of treatment.
Cheilitis was often described as a side effect of etretinate51'53-55, as were pruritus 
and hair loss51'53'54. Skin fragility was described by two authors.51'54 In one case, 
focal osteoporosis was diagnosed 10 months after discontinuation of treatment.51 
Acitretin treatment was very well tolerated, without any side effects.55 The authors 
of one case report concerning etretinate did not describe any adverse effects.52
Conclusion
Grade C
Number of patients treated with etretinate: 21
Etretinate Is an effective treatment for pustular and erythrodermlc psoriasis. 
However, side effects are frequently seen.
The usage of acitretin has not been sufficiently Investigated In childhood psoriasis, 
therefore no conclusions could be drawn.
Ciclosporin
Literature search revealed nine studies on clclosporln as a therapy for childhood 
psoriasis. Three case series78'80 and six case reports81'85 were Identified. Five 
stud les were excluded because of the use of anti psoriatic combination therapies.80' 
83 ,85 Of the remaining four articles, two were classified as LOE 478'79 and two were 
classified as LOE 58182.
A case series of three patients with pustular psoriasis was described In which the 
administered dose was 1 to 2 mg/kg/d.79 Complete disappearance of lesions was 
seen In two patients who were treated for 12 and 6 months, respectively. The third 
patient was still on treatment at time of publication, but showed a significant 
Improvement after five months of treatment. Another patient with pustular psoriasis 
was treated with clclosporln (3 mg/kg/d) In a different article.81 Treatment duration
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was 11 months, after which the patient was free of psoriasis. Ciclosporin in 
photosensitive psoriasis was also described in one patient82, who received a 
dose of 3.5 mg/kg/d, leading to a complete remission after three weeks.
In contrast to the studies described above, one case series78 did not show any 
response. Four patients were treated with ciclosporin, dosage ranging from 2.5 to 
10 mg/kg/d, for 3.5 to 6 months. At the end of treatment none of these patients 
showed a response.
Ciclosporin was very well tolerated in one study.79 The remaining three studies did 
not mention side effects.78 81 82
Conclusion
Grade C
Number of patients treated with ciclosporin: 9
The described efficacy of ciclosporin treatment in childhood psoriasis is 
ambiguous. Safety issues were sparsely described.
Methotrexate
Literature search revealed 10 studies concerning treatment of childhood psoriasis 
with methotrexate (MTX).52'87-95 Two were eliminated because of the use of anti­
psoriatic combination therapies.94 95 The articles included consisted of four retro­
spectively reviewed case series (LOE 4)52 ,87-89 and four case reports (LOE 5)90-93.
A review of 10 cases of childhood psoriasis87 which were treated with MTX showed 
a complete clearance in 20%, almost complete clearance in 60% and no response 
in 10% of cases. MTX was given at an initial dose of 0.03 - 0.24 mg/kg/wk, and 
increased according to patient response to 0.10 - 0.41 mg/kg/wk; duration of 
treatment was 6 to 178 weeks. Authors of all other seven articles administered a 
MTX dosage between 0.2 and 0.4 mg/kg/wk. In all, 24 reviewed cases88 received 
MTX treatment for two to 16 months with an average of 4.97 months. Almost all 
patients (i.e. 91.7%) reached PASI 75, whereas the remaining patients reached 
PASI 50. Another case series of seven patients showed control of disease, 
classified as more than 75% clearance of lesions and minimal scaling and 
erythema, in all patients after 6 to 10 weeks89. Subsequently, dosage was 
decreased to 2.5 mg/wk; total treatment duration was 31.2 - 46.4 weeks. In all 
other cases (n = 8)52'90-93, in which pustular psoriasis was treated, a marked 
improvement to complete remission was reached after 4 to 12 weeks of treatment.
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Mild to severe nausea and vomiting were the most frequently reported side effects: 
in approximately 45% of patients.87,39 In one study, transient minor elevation of 
liver enzymes in the serum was seen in 60% of patients; in one case leading to 
treatment cessation87. Two case reports and one case series failed to describe 
side effects.52'90'93
Conclusion
Grade C
Number of patients treated with methotrexate: 49
MTX is an effective treatment option in moderate to severe childhood psoriasis; 
the largest body of evidence is available for plaque psoriasis. Short-term side 
effects are usually mild and can be treated very well.
Biologies
Extensive literature review revealed 11 publications concerning treatment with 
biologies in children with psoriasis. They consisted of one double-blind RCT95, 
two case series97 99 and seven case reports100“105. Two case reports described two 
treatments; infliximab and etanercept.99'101 In one of these, the treatment period in 
which etanercept was used was excluded because no clear outcome measure 
was stated.101 One study was excluded because of use of an antipsoriatic 
combination therapy.99
In the recent double-blind RCT95 (LOE 1b), 211 children with plaque psoriasis 
were treated with once-weekly subcutaneous injections of etanercept (0.8 mg/ 
kg), with a maximum of 50 mg. At week twelve, 27% of patients treated with 
etanercept reached PASI 90, in contrast to 7% of patients treated with placebo. 
Six other articles (LOE 4 and 5) were found regarding etanercept as a treatment 
in childhood psoriasis97 98'100'102'103'105. Dosage was 0.4 mg/kg or 25 mg twice 
weekly with a treatment duration of 3 to 31 months. One patient with plaque 
psoriasis had no improvement of lesions after eight months of treatment103. Three 
patients had a marked improvement of lesions97 105 and in eight patients complete 
remission was achieved97 98'100'102.
Four case reports (LOE 5) described infliximab treatment in childhood psoriasis.101 
103,104,106 infüximab infusions were given in a dosage of 3.3 - 5 mg/kg. Infusions 
were administered at week 0, 2, and 6, and every 8 weeks thereafter. Treatment 
duration varied from only one administration to 10 months of treatment. All patients 
responded very well. The patient which was treated for 10 months had to finally
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cease treatment because of loss of effect In the long term.101 
Adverse events were described In the etanercept study95 during the open-label 
part: four serious adverse events occurred, among which three Infections (two 
cases of gastroenteritis and one of pneumonia). A serious yeast Infection was 
described In another study with etanercept.100 Mild Injection site reaction was also 
seen In studies with etanercept.98 In eight studies describing Infliximab and 
etanercept no treatment-related side effects were described.97'101105
Conclusion
Grade A
Number of patients treated with etanercept: 117
Etanercept Is an effective biologic In the treatment of plaque type childhood 
psoriasis. Short-term side effects during the treatment period described are 
usually Infections.
A solid conclusion on the efficacy of Infliximab could not be drawn on four 
patients.
Other topical and systemic therapies
The extensive literature search also revealed studies concerning Chinese 
medicine107, exclmer laser108, tazarotene109, wratlzolln110, fumarle acid111, dapsone52' 
112 and prednisone113' 114. As none of these treatments were described In the 
literature as a monotherapy more than once, these studies were excluded. 
Tonsillectomy as a treatment for childhood psoriasis was described twice In the 
found literature. Both were excluded, because they did not state a clear outcome 
measure.115'116
The use of colchicine was described In two case reports.117118 Both articles were 
classified as LOE 4. The first child118 was administered a dose of 0.25 mg three 
times a day, whereas the second one117 was administered a dose of 0.5 mg 
twice-daily. In both cases, the results were excellent.
Both patients treated with colchicine reported mild gastrointestinal symptoms.117118 
Conclusion
Based on the paucity of evidence, a conclusion could not be drawn.
85
Chapter 3.1
Table 3 Summary of included studies
Treatment Author LOE Diagnosis 
(no. of patients)
Study
type
Topical corticosteroids
Halobetasol cream 0.05% Herz et al15 4 PP (11) OL
Clobetasol propionate emulsion 
formulation foam 0.05%
Kimball et al14 4 PP (9); 
Treated (8) 
Placebo (1)
RCT
Hydrocortison ointment 1% Feicht17 5 GPP (1) CR
Vitamin D analogues
Calcipotriol 50 /jg/g Oranje et al18 1b PP (77)
Treatment (43) 
Placebo (34)
RCT
Calcipotriol 50 /jg/g Darley et a l21 4 PP (66) OL
Calcipotriol 0.005% in petrolatum Fabrizi22 4 PP (4); IP (4); 
FP (2); PPP (2)
OL
Calcipotriol 50 /jg/g Park et a l23 4 PP (12) OL
Calcipotriol Travis and 
S ilverberg24
5 EP (1) CR
Calcipotriol 50 /jg/g Patrizi et a l25 4 IP (1); GP (4); 
PP (15)
OL
Calcipotriol Choi et a l26 5 GPP (1) CR
Calcitriol ointment 3 /jg/g Saggese et a l19 2b PP (10) RCT
Calcitriol 15 /jg/g in petroleum jelly Perez et a l20 2b PP (4) PCT
Calcitriol 15 /jg/g in petroleum jelly Perez et a l20 4 PP (4) OL
Calcineurin inhibitors
Tacrolimus 0.1% Brune et a l29 4 FP (5); IP (3); FP 
& IP (3)
OL
Tacrolimus 0.1% Steele et a l30 4 IP (8) ROL
Tacrolimus 0.1% Clayton et a l33 5 FP (1) CR
Pimecrolimus 1% Am ichai31 5 IP (1) CR
Pimecrolimus 1 % Mansouri and 
Farshi32
5 IP & FP (1) CR
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No. of
patients (age)
Duration of 
treatment
Outcome
11 (5-15 y) 14 d Healed: 72.7%; Marked improvement 18.2 %, Moderate 
improvement 9.1%
9 (12-17 y) 2 wk Erythema, induration and thickness of lesions minimal or even 
cleared, and static PGA ‘clear’ or 'minimal': 25% of patients
1 (2 y) 3 wk Clearance 100%
77 (2-14 y) 8 wk PASI: -52% in treatment group, -37.1% in placebo group (= 
not significant); PGA treatment group: clearance 16%, marked 
improvement 44% (in placebo group clearance 0% and 44% 
marked improvement). Differences were statistically significant 
for redness and scaliness, but not for thickness.
66 (2-14 y) 8 wk Mean (±SD) PASI 6.1 (±3.5) -> 2.4 (±1.7) in 8 weeks. Clearance 
or marked improvement in 62-65%.
12 (4-12 y) 4-6 wk Average PASI 3.28 -> 0.28; after 2 weeks PASI50 in 60% of 
patients
12 (8-15 y) 12-106 wk PASI 90: 8.3 %, PASI 75: 66.7%; Mean PASI: 18.4 (±12.2) 6.5 
(±5.4)
1 (4 mo) 3 mo Clearance: 100%
20 (2-13 y) 8 wk >75% improvement: 30%, 50-70% improvement: 45%
1 (6 mo) 1 mo Lesions almost disappeared: 100%
10 (5-17y) 4 wk Residual mild erythema: 100%
4 (13-17 y) 2 mo Severity score (0-9) (±SD): Calcitriol: 6.0 (±0.4) -> 2.5 (±0.6) 
(p<0.025), Placebo: 6.0 (±0.4) 5.8 (±0.3) (p=0.2)
4 (13-17 y) 15-23 mo Mean baseline PASI 11.0 ±2.2 reduced by 94% in 18 months
11 (2-17 y) Maximum 180 d 12% Completely cleared; 88% 90-99% improvement; overall 
severity score clinically significant at day 30
8 (22 mo-16 y) 2 d - 2 wk 100% efficacy in 100%
1 (6 y) 3 d Total clearance: 100%
1 (10 y) 3 wk Lesions resolved: 100%
1 (10 y) 80 d Lesions completely disappeared: 100% after 20 days
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Table 3 C ontinued
Treatment Author LOE Diagnosis 
(no. of patients)
Study
type
Dithranol
Dithranol cream 0.1%-2% Zvulunov et a l35 4 NS (58) ROL
Dithranol cream 0.1% with 
17% urea
Guerrier and 
Porter36
4 GP (6); PP (30); GP 
& PP (5)
OL
Dithranol 0.016%-0.0625% Schubert et a l37 5 PP (1) CR
Phototherapy
NB-UVB 50 mJ initial dose; 
increments of 10% at each session
Jain et a l40 4 GP (2); PP (18) OL
NB UVB Tay et a l43 4 GP (6); PP (4) OL
NB-UVB: starting at 50% of MED 
with increments of 20%
Jury et a l41 4 NS (35) RCS
UVB al-Fouzan and 
Nanda39
4 NS (25) RCS
NB UVB 0.03-0.05 J/cm2 Pasic et a l42 4 GP (3); PP (17) RCS
PUVA Kim et a l44 5 PP (1) CR
PUVA 3.75 mg/L 8-MOP “suit” 
& 2.5-4.0 J/cm2 UVA
Thappa and 
Laxm isha45
5 GP (1) CR
PUVA 0.6 mg/kg methoxypsoralen 
& 0.5 - 1 Joule/cm2 UVA
Braun-Falco 
et a l46
4 EACP (2) CS
Antibiotics
Thiamphenicol 20 mg/kg Juanqin et a l52 4 GPP (2) RCS
Amoxicillin/clavulanic acid 
50mg/kg
Pacifico54 5 GP (1) CR
Erythromycine 50 mg/kg Patrizi et a l53 4 GP (4) CS
Rifampin Rosenberg 
et a l55
4 GP (3); PP (1) RCT
Erythromycine or penicillin V 
with addition of rifampin
Vincent et a l56 4 GP (3) OL
Retinoids
Etretinate 1 mg/kg Rosinska 
et a l61
4 EP (5); GPP (5) RCS
Etretinate 10 mg van de Kerkhof62 5 GPP (1) CR
Etretinate 1 mg/kg Pavicic et a l63 4 GPP (5) CS
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No. of Duration of Outcome
patients (age) treatment
58 (2-15 y) Until remission, Remission (defined as complete disappearance of scaling and
median 2 mo erythema): 81%
41 (3-16 y) 6 wk, extension At week 6: mean percentage clinical improvement (±SEM) 64
to 12 wk for 8 (±11) (n=11) & 77 (±4) (n=23) 
patients
1 (13 mo) 3 mo Marked improvement: 100%
20 (6-14 y) 12 wk >90% PASI reduction: 60%; 70-90% PASI reduction: 15%; 50-
70% PASI reduction: 5%; <50% PASI reduction: 10%
10(14 mo-12y) 6-20 wk (mean 
11.9)
Clearance: 100%
35 (4-16 y) - Clearance or minimal residual disease 63%; 9% no better; 28% 
no record
25 (5-12 y) 7.6 ± 4 wk 
(range 2-20 wk)
>80% clearance: 88%
20 (4-16 y) 10-39 treatments 
(mean 19)
PASI 90: 45%; PASI 70 65%; PASI 50: 85%
1 (17 y) 18 treatments Lesions cleared: 100%
1 (10 y) 4 wk PASI 14.2 -> 1.6 (89% improvement)
2(7-11 y) 15-21 treatments Clearance: 100%
2 (2-12 y) - < 5 0  % Clearance: 100%
1 (7 y) 20 d Cleared 100%
4 (5-10 y) 2 wk Psoriasis completely resolved: 100%
4 (5-10 y) 5 d Excellent response: 25 %, Good response: 75%
3 (12-15 y) 14 d No clinical change: 100%
10 (3-15 y) 3 wk - 12+ mo EP: 2 x complete clearing; 3x improvement; GPP: 5 x complete
clearing
1 (1 y) 3 mo Complete clearance: 100%
5 (3-11 y) - Complete and significant regression of erythroderma: 100%
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Table 3 Continued
Treatment Author LOE Diagnosis 
(no. of patients)
Study
type
Etretinate 0.5-0.9 mg/kg Kim et a l64 4 EP (3) OL
Etretinate 25 mg van der Rhee 
et a l65
4 PP (2) CS
Acitretin 0.5 mg/kg Salieras et a l66 5 EP (1) CR
Ciclosporin
Ciclosporin A 1-2 mg/kg Kilic et a l79 4 GPP (3) CS
Ciclosporin 3 mg/kg Al li et a l81 5 GPP (1) CR
Ciclosporin 3.5 mg/kg Torchia et a l82 5 Photosensitive 
psoriasis (1)
CR
Ciclosporin 2.5-10 mg/kg Mahe et a l78 4 PPP (1); EP (1); 
PP (1); GPP (1)
CS
Methotrexate (MTX)
MTX 0.03-0.24 mg/kg Collin et a l87 4 PP (10) RCS
MTX 0.2-0.4 mg/kg Kaur et a l88 4 PPP (1); EP (3); 
PP (17); GPP (3)
RCS
MTX 0.2-0.4 mg/kg Kumar et a l89 4 EP (3); PP (2); 
GPP (2)
RCS
MTX 0.2-0.4 mg/kg Juanqin et a l52 4 GPP (4) RCS
MTX 0.2 mg/kg Kalla and 
Goya l90
5 GPP (1) CR
MTX 0.4 mg/kg Dogra et a l92 5 GPP (1) CR
MTX 0.3 mg/kg Dogra et a l91 5 GPP (1) CR
MTX 0.3 mg/kg Ivker et a l93 5 GPP (1) CR
Biologies
Etanercept 0.8 mg/kg Palier et a l96 1b PP (211) 
Treated (106) 
Placebo (105)
RCT
Etanercept 25 mg Hoang and 
Burruss100
5 PP (1) CR
Etanercept 0.4 mg/kg Fabrizi et a l102 5 EP (1) CR
Etanercept 0.4 mg/kg Papoutsaki 
et a l97
4 GPP & EP (1); 
PPP (1); PP (2)
CS
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No. of
patients (age)
Duration of 
treatment
Outcome
3 (10-12 y) 4-5 mo Clearance erythema and scaling: 100%
2(8 y) 13-17 mo Excellent: 100%
1 (4 y) 3 mo Complete remission: 100%
3 (10 mo-16 y) 12, 6, 5 mo 
(last one still in 
treatment)
Almost completely disappeared: 33%; Completely disappeared 
66%
1 (9y) 11 mo Free of psoriasis: 100%
1 (15 y) 3 wk Lesions healed: 100%
4 (2-10 y) 3.5-6 mo No response: 100%
10 (5-16 y) 6-178 wk Complete clearance: 20%; Almost complete clearance: 60%, 
No response 10 %
24 (2-14 y) 2-16 mo (mean 
4.97)
PASI 75: 91.7%; PASI 50-75: 8.3%
7 (3-16 y) 6-10 wk to 
control: duration 
31.2-46.4 wk 
(mean 38.8)
> 75% clearance: 100%
4 (2-12 y) - > 80% clearance: 100%
1 (4 y) 10+ wk Marked improvement: 100%
1 (2 y) - Clearance of pustules: 100%
1 (4 y) 12 wk Almost complete remission: 100%
1 (3 mo) 4 wk Clearing: 100%
211 (4-17 y) 12 wk blind;
24 wk open; 12 
wk blind
Treatment-group: PASI 90: 27% (at week 12); PASI 75: 57% 
(at week 12)
Placebo-group: PASI 90: 7% (at week 12); PASI 75: 11%
(at week 12)
1 (14 y) 8 mo Clearance of all lesions except those plaques on elbows 
& knees 100%
1 (22 mo) 6 mo PASI 37 —> 1.2 in 12 weeks
4 (6-15 y) 24-86+ wk PASI: 25.8 0; 21.2 0; 27.4 5.9; 9.2 2.2
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Table 3 Continued
Treatment Author LOE Diagnosis 
(no. of patients)
Study
type
Etanercept 0.4 mg/kg Safa et a l105 5 EP (1) CR
Etanercept 25 mg Farnsworth 
et a l103
5 PP (1) CR
Etanercept 0.4 mg/kg K ress98 4 PP (3) CS
Infliximab 5 mg/kg Farnsworth 
et a l103
5 PP (1) CR
Infliximab 3.3 mg/kg Menter and
Cush104
5 PP & PPP (1) CR
Infliximab 5 mg/kg Pereira et a l101 5 GPP (1) CR
Infliximab 5 mg/kg Weishaupt 
et a l106
5 GPP (1) CR
Other therapies
Colchicine 0.5 mg Zachariae 
et a l118
5 GPP (1) OL
Colchicine 0.25 mg Wahba and 
Cohen117
5 GP & PP (1) OL
CR case report NB narrowband
CS case series NS not specified
EACP erythema annulare centnfugum-type OL open-label trial
psoriasis PASI Psoriasis Area and Severity Index
EP erythrodermlc psoriasis PCT placebo-controlled trial
FP facial psoriasis PGA Physician Global Assessment
GP guttate psoriasis PP plaque psoriasis
GPP pustular psoriasis PPP palmoplantar psoriasis
IP Inverse psoriasis PUVA psoralen plus ultraviolet A
LOE level of evidence RCS retrospectively reviewed case series
MED minimal erythema dose RCT randomized controlled trial
MOP methoxypsoralen ROL retrospectively reviewed open-label trial
MTX methotrexate UV ultraviolet
92
Treatments for childhood psoriasis
No. of
patients (age)
Duration of 
treatment
Outcome
1 (7y) 6+ mo Significant clinical improvement: 100%
1 (14 y) 8 mo No improvement:100%
3 (9-16y) 27; 27; 30 mo Almost clear 100%
1 (14 y) 6+ wk Marked clearing of psoriasis: 100%
1 (13 y) 30+ wk Trunk and limb plaques cleared, with significant improvement of 
the palmoplantar disease: 100%
1 (3 y) 10 mo Completely clear: 100% in 2 wks, after 13 wks flare, after 10 mo 
insufficient effect
1 (16 y) 1 administration Pustules resolved, erythema lightened: 100%
1 (12 y) - Symptoms disappeared: 100%
1 (4 y) 2 mo Excellent: 100%
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Discussion
Literature concerning treatment efficacy and safety in childhood psoriasis is 
diverse. After thorough inspection of all literature, 64 studies could be included, 
describing 646 children in total. Of these 64 studies, only six were RCTs. Because 
of the paucity of RCTs, all LOEs were included in this study.
Most literature concerns induction of remission, rather than maintenance therapy. 
Although some studies describe treatment durations of up to almost 3.5 years87, 
these are exceptional and comprise only a few cases. Similar data on the follow-up 
period and duration of remission are limited, as they are on the safety issues 
described. None of the studies mentioned long-term safety profiles of the 
treatments described. Thus, in the discussion below, efficacy refers to the 
induction of remission, and safety is restricted to short-term safety. 
Implementation of the results on topical corticosteroids, calcipotriol, calcineurin 
inhibitors and dithranol and their grades of recommendation in a treatment 
algorithm is discussed below.
Long-term side effects of phototherapy (e.g. photo ageing, carcinogenesis) have 
been seen in the treatment of adults119 and children120. A relationship between 
melanoma and UV radiation has been found.121 In addition, anxiety can be a 
significant problem in the paediatric group.41 Given the aforementioned 
considerations, we conclude that NB-UVB should not be used in toddlers and 
infants. In adolescents, it should be used carefully, especially if they have fair skin. 
In contrast to two earlier publications (including a Cochrane review) in which 
treatment with antibiotics in guttate psoriasis was reviewed122'123, we only included 
studies reporting on the efficacy in children. The use of antibiotics in the treatment 
of childhood guttate psoriasis remains controversial.
Of the 22 children in whom retinoid treatment was described, 21 were treated with 
etretinate and its metabolite acitretin was administered to only one patient. All 
patients but two had pustular and erythrodermic psoriasis. An apprehension is 
that skeletal toxicities might occur in children on long-term retinoid therapy. In 
addition, all retinoids are known to be potent teratogens and the major concerns 
in treating fertile women with oral retinoids are fetal deformities.124 Therefore, we 
advise to save retinoids for short-term treatment of pustular or erythrodermic 
psoriasis in infants and male adolescents.
The efficacy of ciclosporin in childhood psoriasis remains unclear. In the articles 
included, safety issues are rarely discussed. Studies have been published in 
which the drug is tolerated by children (in which ciclosporin was indicated for
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another disease) at least as well as in adults.125 Treatment periods of up to one 
year have been described in which the drug was well tolerated.125 Nonetheless, 
caution should be taken, particularly in children, because ciclosporin has the 
potential of cumulative toxicity.125 Based on the ambiguous efficacy as described 
in this review, treatment with ciclosporin should not be the systemic therapy of 
choice in childhood psoriasis.
The efficacy and safety of MTX in childhood psoriasis was described in a total of 
49 patients. Long-term safety and efficacy of MTX in the treatment of childhood 
psoriasis has not been investigated to date. However, in juvenile idiopathic 
arthritis, this drug was often used for long periods of time and has a track record 
of safe and effective use.127 In juvenile idiopathic arthritis MTX is described as the 
second-line agent of choice.128 In case of a moderate to severe childhood plaque 
psoriasis, which is recalcitrant to local therapies, we consider MTX to be the 
systemic treatment of choice.
The efficacy and short-term safety of etanercept were studied in a large 
double-blind RCT (n = 211). Long-term side effects and risks were not described, 
as this drug has only recently been introduced for the indication of childhood 
psoriasis. In patients with juvenile rheumatoid arthritis, a study into safety and 
efficacy of up to eight years of continuous etanercept therapy was recently 
published. The authors state that long-term continuous treatment with etanercept 
was well tolerated for up to eight years, without an increase in the rates of serious 
adverse events over time.129 Although this new treatment modality for childhood 
psoriasis seems very promising, vigilance is called for.
In conclusion, all available literature concerning treatment modalities of childhood 
psoriasis was described and assessed in this systematic review. Unfortunately, 
most of the evidence is of a low level, i.e. grade C and D. Only some studies 
describing treatment with calcipotriol and etanercept have higher LOEs (i.e. level A). 
Clearly, there is a need for randomized placebo-controlled trials in childhood 
psoriasis.
In Fig. 1 we present our recommendations based on the literature review described 
above. With these recommendations we hope to stimulate a fruitful discussion on 
this very important issue.
The treatment of choice in mild or moderate childhood psoriasis should be 
calcipotriol, if necessary, combined with mild to moderate topical corticosteroids. 
In case of treatment-resistant flexural and/or facial psoriasis, tacrolimus 0.1% can 
be added to the treatment regimen. If this treatment regimen is not effective, or if 
psoriasis is moderate to severe, treatment with dithranol is recommended. Only
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in case of lack of efficacy of these modalities, treatment with NB-UVB can be 
considered In adolescents, but only for a short duration. Although controversial, 
the use of antibiotics can be considered In case of guttate psoriasis and suspicion 
of a streptococcal Infection.
Of the systemic treatments, MTX Is regarded as the therapy of choice. Retinoids 
should be considered In cases of pustular and erythrodermlc psoriasis. Treatment 
with clclosporln should only be deliberated In exceptional cases. Etanercept Is a 
very promising newtreatment modality, which should be considered as a third-line 
drug. Specialized centres should make alliances to provide an extensive database 
In which all systemic treatments will be recorded. Only then can evidence-based 
data be extracted on which solid conclusions can be drawn In the future.
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Figure 1 Treatment algorithm
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Abstract
Introduction
In childhood psoriasis, physicians aim for an effective and safe treatment, such 
as with dlthranol. This study presents the largest study of dlthranol-treated 
patients described In the literature.
Objective
The aim of the study was to determine the position of dlthranol In the treatment 
strategy of psoriasis.
Methods
All juvenile patients receiving dlthranol treatment at our centre were evaluated 
retrospectively.
Results
Sixty patients (with 82 treatment episodes In total) were Included. The mean age 
at the start of dlthranol treatment was 11.1 years (range 3.7 - 17.9). The result of 
treatment was: excellent (3.7%), good (69.5%), moderate (8.5%), reasonably 
(13.4%) or disappointing (4.9%). Mild Irritation was seen In 39% and severe 
Irritation was seen In 63% of the patients.
Conclusions
Dlthranol can be regarded as an efficacious and safe topical therapy for the 
treatment of childhood psoriasis. It Is a valuable alternative topical treatment 
which should not be disregarded In the treatment regimen of childhood psoriasis 
and should be commenced before ultraviolet or systemic treatments are 
Initiated.
Dithranol therapy in childhood psoriasis
Introduction
Dithranol is one of the oldest topical therapeutics for psoriasis. More than 130 
years ago, chrysarobine was shown to have an antipsoriatic effect. In 1916, 
dithranol, a synthetic derivative of chrysarobine, was developed by Galewski1 
and, from that time on, it was used in psoriatic patients in Europe2. As a result of 
the development of short-contact therapy with dithranol creams and ointments in 
the early eighties, the use of this topical agent has become more convenient over 
the years. The exact mechanism of action is still unknown, but it is known to 
induce a cascade of free radicals in the skin, resulting in antiproliferative effects 
and a modulation of inflammation in psoriasis.3 No serious side effects of dithranol 
have been reported. It may cause a burning sensation, irritation and staining at 
the application site or clothing.
Especially in childhood psoriasis, there is a need for effective treatments without 
serious side effects. Even more than in adults, long-term side effects have to be 
minimized. As dithranol treatment has a long history of more than 100 years, and 
no serious side effects have been mentioned in the literature, dithranol is regarded 
as a safe treatment. To our surprise, despite one century of application in the 
treatment of psoriasis, only two studies have been performed concerning the use 
of dithranol in children.4:5
In order to bring forward more evidence on the safety and efficacy of dithranol in 
childhood psoriasis, the largest series of patients with juvenile psoriasis treated 
with dithranol is presented in our study.
Methods
All juvenile patients (aged < 18 years) receiving dithranol treatment at our medical 
centre between 1 January 1990 until 1 June 2009 were included in this study. 
Dithranol short-contact therapy was given at the daycare unit, using the instruction 
principle of daily visits during the first weeks and, thereafter, twice-weekly visits. 
Usually, visits last 30 - 60 min. Dithranol cream (0.01 - 4%) is diffusely applied on 
the trunk, arms and legs. The concentration is gradually increased after nine 
consecutive days of treatment, according to the tolerance and therapeutic 
response of the patient. Within these nine days, the dithranol cream is applied for 
15 minutes at day 1 - 3, for 30 minutes at day 4 - 6, and for 45 minutes at day 7 - 9. 
It is washed off by shower and, afterwards, an emollient is applied on the treated
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skin. An episode of dithranol treatment is finished if clearance or almost clearance 
is achieved or if, despite increasing the concentration of dithranol, no further 
favourable results are achieved. At the end of a dithranol treatment episode, 
predesigned data forms are completed by the dermatologist and added to the 
patient’s records. These forms did not change in the period from 1990 until 2009. 
Therefore, although outcome measures are descriptive, they are standardized. 
After the dithranol treatment episode is finished, patients receive prescriptions for 
low- to mid-potency topical corticosteroids and/or vitamin D analogues to be 
applied to small lesions if necessary. Multiple episodes of dithranol treatment in 
one patient were scored separately. Predesigned data extraction forms were used 
to record extracted data on treatment characteristics. The treatment outcome was 
determined at the end of each treatment episode. This outcome was rated as 
disappointing, reasonable, moderate, good (almost clearance) or excellent 
(clearance). End of remission is defined as the date on which more potent 
therapies (than the treatments prescribed at the end of dithranol treatment) were 
needed to control the disease. Other treatment characteristics included age at 
the start of treatment, antipsoriatic medication history, total duration of treatment, 
minimum and maximum concentration of dithranol, duration of remission, duration 
of follow-up and adverse events. Concomitant medication was registered 
throughout the whole period of dithranol treatment. The side effect irritation was 
divided in mild irritation and severe irritation. Severe irritation was defined as 
irritation due to which dithranol therapy was interrupted or adapted or topical 
corticosteroids were needed. All other cases of irritation were classified as mild 
irritation.
Descriptive statistics were provided using mean (± SD) or median (with 
interquartile ranges (IQR); 25th - 75th percentile) values depending on the (non-) 
parametric distribution of the measured variables. Statistical analysis was 
performed using SPSS16 (SPSS Inc., Chicago, IL, USA).
Results
Sixty patients were eligible for inclusion in the study. Altogether, they received 82 
treatment episodes with short-contact dithranol applications. Forty-four patients 
received one episode of dithranol treatment, 12 patients received two episodes, 
three patients received three episodes and one patient received five episodes of 
treatment with dithranol. The mean age at the start of dithranol treatment was 11.1
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years (SD: 4.0; range 3.7 -17.9 years). Before dithranol treatment was initiated, the 
patients had already been treated with several other antipsoriatic therapies. 
Topical corticosteroids had been used prior to dithranol therapy in 90.2% of the 
patients. The different potencies of corticosteroids used are depicted in Table 1. 
Vitamin D analogues had been used in 60.0% and ultraviolet B (UVB) therapy in 
46.7% of patients prior to therapy. The remaining therapies that had been used 
before initiation of dithranol treatment are also presented in Table 1.
Table 1 Therapies of study patients prior to dithranol treatment
Therapies
Topical corticosteroids
■ Class I (e.g. hydrocortisone acetate)
■ Class II (e.g. triamcinolone acetonide)
■ Class III (e.g. betamethasone valerate)
■ Class IV (e.g. clobetasol propionate)
Vitamin D analogues
Calcineurin inhibitors
Calcipotriol / betamethasone dipropionate 
Coal tar cream / solution carbonis detergens 
Keratolytic ointment 
Ultraviolet B therapy
Dithranol (in other medical centres or home-treatment)
Methotrexate
Ciclosporin
Retinoids
Percentage of patients
90.2
13.3
40.0
80.0
28.3 
60.0
1.7 
10.0
36.7
36.7
46.7
11.7
3.3
3.3 
5.0
The median minimal concentration of dithranol cream was 0.05% (IQR: 0.05 - 
0.1%; range 0.01 - 0.10%), whereas the median maximum concentration was 0.2% 
(IQR: 0.1 - 0.4%; range 0.01 - 4.0%). The median increase in concentration was 
0.1% (IQR: 0.05 - 0.35%). The duration of a treatment episode had a median of 
65.0 days (IQR: 42.0 - 103.75). In 22.9% of the patients, lesions were pre-treated 
with 5% salicylic acid in orderto reduce desquamation. Solutio carbonis detergens 
10% was used in 5.4% of the patients after dithranol cream had been washed off.
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A good result (almost clearance) was achieved In 69.5% of the patients, whereas 
3.7% had total clearance of lesions (excellent result). The treatment outcome was 
moderate In 8.5% of the patients, while 13.4% had a reasonable result. In 4.9%, 
the treatment outcome was disappointing.
After treatment, the duration of remission was measured. For 22 treatment 
episodes, the remission period could not be evaluated. The remaining 60 
treatment episodes had a median remission duration of 5.5 months (IQR: 1.0 - 
18.0). The median follow-up duration was 12.5 months (IQR: 2.8 - 54.0). 
Subanalyses were performed for 16 patients with more than one treatment 
episode. During the second treatment episode, median concentrations used 
were almost equal to those of the first episode. The median duration of treatment 
was 24 days longer than the Initial episode (87 days versus 53 days); on the other 
hand, the median duration of remission was six months longer (first episode five 
months; second episode 11 months). In this subgroup of 16 patients, the result of 
the second treatment episode was somewhat better than that of the first episode. 
Only four patients had more than two treatment episodes. Therefore, analyses of 
the third, fourth and fifth episodes were not carried out because these were not 
representative due to the limited amount of patients.
The only side effect described was Irritation; mild Irritation was seen In 39% of the 
patients and severe Irritation was seen In 63%. During the median treatment 
duration of 65.0 days, mild Irritation occurred with a median of one time per 
treatment episode and severe Irritation was seen a median of 1.5 times per 
treatment episode. None of the patients discontinued treatment because of side 
effects.
Discussion
These real-practlce clinical data have been retrieved from the detailed patient 
records of our daycare unit. These results demonstrated that short-contact 
dlthranol treatment has been an effective and safe treatment modality In as many 
as 73% of our children with psoriasis. A median treatment period of two months 
was needed to establish a median duration of remission of 5.5 months. This Is 
comparable with results from a previous study on children, where a median 
treatment duration of two months resulted In a median remission duration of four 
months.4 These results are superior to those of a study from 1983, In which less 
than 40% had more than 75% Improvement In lesions after six weeks.5 Dlthranol
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treatment of adults at daycare centres has been reported to result In clearing In 
63 - 77% of the patients after 14-42 treatment days.5 8
Dlthranol therapy Is quite time-consuming for children and parents, especially In 
the first week when dally visits to the daycare unit are necessary. Consequently, 
absence from school can be a problem. Staining of skin, clothes and bathtubs 
should also be discussed at the start of treatment.
Although Irritation was a relatively frequently seen side effect, we consider 
dlthranol treatment to be a safe treatment. No side effects were seen during the 
follow-up period (median: 12.5 months), which Is also supported by the literature, 
In which no mid- to long-term side effects are reported.9 In the study by Zvulunov 
et al., 20% of the patients had adverse skin reactions such as mild transient skin 
Irritation and staining; one patient ceased treatment due to these side effects.4 In 
the treatment regimen of the former study, dlthranol cream was only applied to 
the lesions. This could explain the fact that In the current study, where dlthranol 
was applied diffusely, 73% of the patients had side effects. Nevertheless, none of 
our patients ceased treatment.
One of the alms of the study was to re-evaluate the position of dlthranol In the 
treatment algorithm of childhood plaque psoriasis. In comparison with dlthranol, 
ultraviolet (UV) therapy has a comparable treatment outcome and treatment 
duration.10 Although there are no studies documenting the long-term safety of 
UVB phototherapy for childhood psoriasis, judicious use of this therapy Is advised 
for appropriately selected patients as a second-line therapy, I.e. for children 
whose disease falls topical therapy.11 For dlthranol, no long-term side effects have 
been described.9 Additionally, dlthranol Is only applied for a few months. Systemic 
treatments (such as methotrexate and etanercept) are usually used for a longer 
period. Again, more serious and long-term side effects can be seen In case of 
systemic treatments. Therefore, In our opinion, dlthranol should be commenced 
before UV and systemic treatments.
In this retrospective study, outcome measures were descriptive, but In a 
standardised way. Because the Psoriasis Area and Severity Index was not used, 
the severity of psoriasis at the beginning of the dlthranol treatment could not be 
described objectively. In our department, however, dlthranol treatment Is Initiated 
In case of moderate to severe psoriasis as It Is a fairly time-consuming treatment 
and not easily accessible.
In conclusion, dlthranol can be regarded as an efficacious and safe topical 
therapy for the treatment of childhood psoriasis. Even though It Is a classic, rather 
time-consuming therapy, with obvious disadvantages such as Irritation and
Chapter 3.2
staining, it is a valuable alternative topical treatment which should not be 
disregarded in the treatment regimen for childhood psoriasis. Consequently, 
before UV or systemic treatment is initiated in children with psoriasis, dithranol 
treatment should be considered.
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Abstract
Background
Chronic diseases can have a great influence on health-related quality of life. 
Nevertheless, only little research has been carried out on childhood psoriasis. 
The perception of quality of life by adults with psoriasis of their childhood psoriasis 
has never been investigated.
Objectives
The aims of this study were to (i) investigate retrospectively the influence of 
psoriasis as experienced in childhood as compared with the current quality of life 
in adulthood; (ii) assess retrospectively the impact of childhood psoriasis on daily 
life; and (iii) compare the current quality of life in patients with childhood onset 
psoriasis (COP) and adult onset psoriasis (AOP).
Methods
A survey was performed among all members of the Dutch Psoriasis Society. 
Validated questionnaires on quality of life, impact on daily life and clinical severity 
were used.
Results
Questionnaires of 1762 patients were suitable for analysis. Adults with an onset of 
psoriasis before the age of 18 years retrospectively rate their quality of life during 
childhood much less as compared with their current quality of life (intrapatient 
comparison). Influence of psoriasis in childhood particularly had a high degree of 
limitations on recreational and social activities in 15 - 30% of patients. Quality of 
life in adulthood is not determined by age of onset of psoriasis.
Conclusions
In childhood, the quality of life is greatly influenced by psoriasis. The social 
development domain, which is one of the developmental milestones in a child, is 
particularly impaired. The current quality of life of patients with COP is equal to 
that of patients with AOP.
Impact of childhood onset psoriasis
Introduction
Psoriasis is a common, inflammatory, chronic relapsing skin disease affecting 
approximately 2% of the worldwide Caucasian population.1 Of the adult psoriatic 
patients, 35 - 50% indicates that the skin disease started before the age of 20.2 5 
Having a chronic disease in childhood can diminish a child’s health-related quality 
of life.5 Negative life experiences, such as a chronic disease in childhood, may 
also have an influence on development during childhood and on adult life.7 
In dermatological research, quality of life studies in children mainly focus on 
atopic dermatitis, demonstrating the burden atopic dermatitis has on children.5:810 
In view of the comparable impact of atopic dermatitis and psoriasis in adult 
patients,11 it could be assumed that childhood psoriasis also has a comparable 
impairing influence on the quality of life of the children with these skin conditions. 
To the best of our knowledge, there are only two studies that systematically 
examined the quality of life of children with psoriasis, demonstrating that the 
quality of life of children with psoriasis is even worse than in diabetes and epilepsy 
in childhood.5:12 In adult psoriatic patients, many studies have been performed on 
the quality of life.1318 Whether the age of onset of psoriasis (childhood onset vs. 
adult onset) influences the quality of life later in adulthood was never investigated. 
It could be assumed that having psoriasis as a child influences the quality of life in 
adult life.
The following questions were formulated: (i) How do adult psoriatic patients with 
childhood onset psoriasis retrospectively evaluate the quality of life in their 
childhood? And how does this relate to their current quality of life? (ii) How do 
adults retrospectively assess the quality of life of their childhood with respect to 
daily life? (iii) Does the age of onset of psoriasis (childhood onset vs. adult onset) 
influence the quality of life in the long term?
Methods
Study population
All 5300 (adult) members of the Dutch Psoriasis Society were enrolled in the present 
study and were sent a questionnaire. Responses were gathered from 14 February 
2009 to 1 June 2009.
Patients were subdivided into two groups depending on the age of onset of 
disease. The first group consisted of patients who experienced an onset before
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the age of 18 years (childhood onset psoriasis (COP)); the second group 
comprised patients with an onset of disease from the age of 18 years (adult onset 
psoriasis (AOP)).
Measures
Quality of life over the past year was assessed by the Dermatology Life Quality 
Index (DLQI).19:20 The DLQI is a validated, self-administered, simple tool to measure 
how much a skin problem has affected the life of a patient. It consists of 10 
questions concerning patients’ perception of the impact of skin diseases on 
different aspects of their quality of life. It has been validated for dermatology 
patients aged 16 years and above. For this study a validated Dutch version was 
used. The items of the DLQI encompass aspects such as symptoms and feelings, 
daily activities, leisure, work or school, personal relationships and the side effects 
of treatment. Each item is scored on a four-point Likert scale: 0, not at all / not 
relevant; 1, a little; 2, a lot; and 3, very much. Scores of individual items (0 - 3) are 
added to yield a total score (0 - 30); higher scores mean greater impairment of the 
patient’s quality of life.
Quality of life in childhood was questioned retrospectively with the DLQI, because 
the Children’s Dermatology Life Quality Index (CDLQI) is not validated for adults. 
The questions from the DLQI were addressed for the period before the age of 18 
years in patients with COP. Patients were instructed to fill out the DLQI for their 
average situation in childhood (i.e. until the age of 18 years) in case they had 
COP. For the comparison of DLQI in childhood and adulthood, patients served as 
their own control.
Impact of COP on daily life was measured by means of an adapted question 
derived from the Impact of Chronic Skin Disease on Daily Life (ISDL) questionnaire 
concerning this subject.21 This 10-item generic scale measures the effect the 
condition has on activities of daily life including work, hobbies, holiday, sleep, 
sexuality, eating and relationships, with response categories on a four-point Likert 
scale (1, not; 2, a little; 3, strongly; 4, totally). Apart from the separate item scores, 
a total impact score can be calculated to reflect the overall impact of the disease 
on daily life. The total score ranges from 10 to 40.
Clinical severity of psoriasis was assessed by a Patient Global Assessment (PGA) 
and the Self-Administered Psoriasis Area and Severity Index (SAPASI)22. The PGA 
was rated on a scale from clear to very severe (0 - 5). Patients were asked to rate 
the current PGA and their (retrospective) PGA during childhood. The SAPASI is a 
one-page instrument consisting of silhouettes (front and back) of the human
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body, on which patients shade areas currently affected by psoriasis. The shaded 
areas are assigned a numerical value of 0 to 6 for the four body regions (head, 
upper extremities, trunk and legs) by a physician as follows: 0, no involvement; 1, 
< 10%; 2, 10 - 29%; 3, 30 - 49%; 4, 50 - 69%; 5, 70 - 89%; 6, 90 - 100%. Patients 
also had to rate the average redness, thickness and scaliness of their lesions by 
means of three visual analogue scales (VAS). Similar to the PASI, scores on the 
SAPASI range from 0 to 72. Evidence of validity and reliability for this instrument 
has been provided by several studies.22 25
Statistics
Mean, standard deviation (SD) and range were calculated for all variables; 
comparisons of numeric variables were analyzed with the Student’s f-test, paired 
f-test and %2test as appropriate. P-values < 0.0025 were considered as statistically 
significant for the main hypotheses due to Bonferroni’s correction for multiple 
testing. Statistical analysis was performed using SPSS16 (SPSS Inc., Chicago, 
IL, USA).
Results
Sample characteristics
The questionnaires were sent to 5300 psoriatic patients, of which 1963 (37.0%) 
were returned. Due to missing values, questionnaires of 1762 patients were suitable 
for analysis. The mean age of the respondents was 55.4 years (SD ± 13.3). 
Among the responders were 871 (49.4%) men and 891 (50.6%) women. Mean 
duration of psoriasis was 28.9 years (SD ± 15.2), ranging from 0 to 81 years. 
Mean age of onset of psoriasis was 26.5 years (SD ± 15.4); mean age at diagnosis 
of psoriasis was 28.3 years (SD ± 15.6). Mean age of onset was 27.6 years in men 
and 25.4 years in women (f-test; p = 0.003).
The total group of 1762 respondents was divided into two groups according to the 
age of onset of psoriasis: COP (onset of psoriasis < 18 years) consisted of 568 
patients (32.2%) and AOP (onset of psoriasis > 18 years) comprised 1194 patients 
(67.8%). There was a preponderance of women in the COP group (women: 62.3%), 
in comparison with the AOP group (women: 45.0%) (%2; p < 0.001). A majority of 
patients (51.5%) indicated that they were currently being treated by a dermatologist. 
On the other hand, 512 (29.3%) respondents were not currently treated by any 
medical professional for their skin disease. In view of treatment by a medical
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professional, there were no significant differences between patients with COP 
and AOP (x2; p = 0.233).
Intrapatient comparison quality of life in childhood and adulthood
The retrospectively measured DLQI in childhood had a mean of 12.8 (SD ± 7.5). 
This mean value was significantly higher compared with the current mean DLQI of 
6.8 (SD ± 5.7) of COP patients (f-test; p < 0.001). Subanalyses of separate items 
showed significantly higher scores for the DLQI in childhood for all questions 
compared with the current scores (f-test; p < 0.001). Generally, the retrospec­
tively reported PGA was somewhat higher in childhood compared with adulthood 
(2.9 (SD ± 1.1) versus 2.4 (SD ± 1.0) respectively; f-test; p < 0.001).
Impact of childhood psoriasis on daily life
The impact of childhood psoriasis on daily life was retrospectively assessed by 
the ISDL impact scale in patients with COP. The average total score of the ISDL 
was 16.4 (SD ± 5.6). In patients who were currently being treated by a dermatologist, 
the average total score was 16.9 (SD ± 6.0). In Table 1, answers per question are 
displayed for all COP patients. Vacation and leisure time were affected in more 
than 60% of patients, whereas hobbies, sexuality and contact with friends were 
affected in morethan 50%. In 15 - 30% ofthese patients, these areas were strongly 
or even totally influenced by the psoriasis in childhood.
Comparison current quality of life
Mean total score of the DLQI for the quality of life in the past year was 6.8 (SD ± 
5.7). For COP the total score of the current DLQI was 6.8 (SD ± 5.6) compared 
with 6.9 (SD ± 5.8) in AOP (f-test; p = 0.735). Differences between individual 
questions were also not significant. The mean PGA was not significantly different 
between both groups: COP-group 2.38 and AOP-group 2.41 (f-test; p = 0.495). 
The SAPASI score in COP patients was somewhat higher than in AOP patients 
(7.0 versus 6.5; f-test; p = 0.014).
The results were the same for the subgroups of patients who were currently 
treated by a dermatologist or not.
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Table 1 Im pact of ch ildhood  pso rias is  on da ily  life
Did the severity of psoriasis in your childhood had a negative influence on:
Number of Not 
patients n (%)
A little
n (%)
Strongly
n (%)
Totally
n (%)
Work/School 564 320 (56.3) 155 (27.3) 59 (10.4) 30 (5.3)
Household chores 554 443 (78.0) 92 (16.2) 9(1.6) 10 (1.8)
Hobbies 560 274 (48.2) 173 (30.5) 84 (14.8) 29 (5.1)
Vacation 567 172 (30.3) 223 (39.3) 127 (22.4) 45 (7.9)
Leisure time 563 212 (37.3) 217 (38.2) 102 (18.0) 32 (5.6)
Sexuality 564 270 (47.5) 175 (30.8) 71 (12.5) 48 (8.5)
Eating habits 566 410 (72.2) 121 (21.3) 27 (4.8) 8(1.4)
Sleeping 566 417 (73.4) 98 (17.3) 37 (6.5) 14 (2.5)
Contact with friends 568 242 (42.6) 239 (42.1) 59 (10.4) 28 (4.9)
Contact with family 568 417 (73.4) 122 (21.5) 15 (2.6) 14 (2.5)
Relationship 488* 333 (58.6) 127 (22.4) 21 (3.7) 7(1.2)
Family life 422* 325 (57.2) 81 (14.3) 13 (2.3) 3 (0.5)
* As these items are questions about childhood psoriasis, these questions are not applicable 
to all patients.
Discussion
The diagnosis of childhood psoriasis raises the question among parents as to the 
extent to which this diagnosis can influence the quality of life of their child now 
and in the future.
With patients serving as their own control, retrospectively assessed DLQI scores 
(total scores and scores of separates questions) are significantly higher (i.e. less 
quality of life) in childhood (12.8) than the current DLQI scores in adulthood (6.8). 
Adult patients thus experienced their quality of life much worse during their 
childhood as compared to their current situation. This could be due to the fact 
that psoriasis has genuinely more impact in childhood; it is also possible that a 
few decades ago, treatment options for childhood psoriasis were more distressing. 
Another explanation could be that due to the retrospective design of this study a 
recall bias has occurred. Regardless of the reason for this higher retrospective
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quality of life score in childhood is, the fact is that this is rated by the adults now. 
One can infer from the data that childhood psoriasis is experienced as incriminatory 
not only in adulthood, but also in childhood. So far, CDLQI scores in juvenile 
psoriasis have been measured in only two studies in patients who visited the 
dermatology outpatient department, indicating a relatively high impact of psoriasis 
on daily life of children.5112 Also, comparative CDLQI scores in children with atopic 
dermatitis were found in other studies.5:810 Together with the high scores found in 
our study, when the quality of life in childhood psoriasis is retrospectively 
assessed, these results suggest that the impact of childhood psoriasis is at least 
as severe as in atopic dermatitis and can have an impairing influence on the 
development of children. In addition, our results of the ISDL scores showed that 
the influence of juvenile psoriasis on recreational and social activities (e.g. 
vacation and hobbies) is large in 15 - 30% of respondents. Accordingly, the social 
development domain, which is one of the developmental milestones in a child, is 
particularly impaired. In contrast, the quality of life and severity of the disease in 
the long term were not determined by the age of onset of psoriasis, as the current 
quality of life and disease severity scores of the COP- and AOP-group were 
comparable in adults. The conclusion could be drawn that, also in childhood, the 
burden of psoriasis is considerable and should not be underestimated, whereas 
quality of life in later life is not determined by the age of onset of psoriasis. 
However, several limitations should be considered. The main limitation of this 
study is the retrospective design. Consequently, this could cause a recall bias, 
which might possibly have resulted in an overestimation or underestimation of the 
severity and impact of childhood psoriasis on daily life. Obviously, a prospective 
study would have given more reliable data. As the questionnaires were only sent 
to members of the Dutch Psoriasis Society, a selection bias could be present. 
Patients in whom psoriasis only occurred on childhood are possibly missed, 
because they might not be members of the Dutch Psoriasis Society in 
adulthood.
In summary, the current study shows that (i) retrospectively, adults rate their 
quality of life during childhood much less as compared with their current quality 
of life in adulthood, (ii) the influence of psoriasis in childhood causes a high 
degree of limitations on recreational activities in at least 15 - 30% of patients. 
Therefore, the social development domain, which is one of the developmental 
milestones in a child, is particularly impaired and (iii) the quality of life in the long 
term is not determined by the age of onset of psoriasis.
In clinical practice, there is a great challenge for dermatologists to improve the
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quality of life of children with psoriasis. To do so, greater attention should be paid 
to the possible limitations that these children experience. As one could assume 
that improving the severity of psoriasis has a positive influence on quality of life, 
the outcome of quality of life measurements should be taken into account when 
deciding on treatment strategies. As a child-tailored treatment could limit the 
psychological impact of the disease, a more active disease-modifying approach 
should be considered to optimize and individualize the treatment. This might also 
considerably improve the quality of life of children with psoriasis.
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Abstract
A pilot study on the impact on quality of life in childhood psoriasis is presented. 
Of the children interviewed, 65% experienced stigmatization to a certain extent, 
71% reported itch and 43% complained about fatigue. Clinicians should pay 
attention to these items, in order to initiate a patient-tailored treatment.
The burden o f ch ildhood psoriasis
Psoriasis in childhood has a prevalence of approximately 0.7%.1 Evaluation of 
quality of life (QoL), defined as physical, emotional and social functioning, can 
display unmet medical and psychological needs of children with psoriasis. 
Unfortunately, this was only described in one study so far. In this study, the QoL 
was even worse than in diabetes and epilepsy in children.2 Our purpose was 
to explore physical, emotional and social limitations children with psoriasis have 
to cope with in a pilot study.
Systematic, semi-structured interviews were held with 15 children with psoriasis 
(with their parents present) (i.e. age < 18 years). For this pilot study, the 
participating patients were randomly selected from a general population database. 
QoL was assessed with the Children’s Dermatology Life Quality Index (CDLQI) 
questionnaire.2 Stigmatization, severity of skin lesions and physical symptoms 
(degree of itch, pain and fatigue on a visual analogue scale (VAS)) were assessed 
with scales from the Impact of Chronic Skin Disease on Daily Life (ISDL) 
questionnaire.3 Higher scores imply more feelings of stigmatization, more 
extended psoriasis, and more itch, pain and fatigue. All questionnaires were filled 
out by the children or exceptionally by the parents according to the answers given 
by their child.
Sample characteristics are depicted in Table 1.
From the interviews, it appeared that approximately half of the children felt 
stigmatized as they were bullied or called names. Three children said that they 
had been asked by others if lesions were contagious. One girl felt isolated because 
others did not want to play with her. Four children felt ashamed of their skin. 
Scores on the CDLQI, seventy-scale, stigmatization-scale, and the VAS are shown 
in Table 2. As can be appreciated by the severity score, most children had a mild 
psoriasis. Itch was experienced (VAS > 2) by 71% of children (n = 10), pain by 
21% (n = 3) and fatigue by 43% (n = 6). Almost 65% of the patients experienced 
stigmatization; of this subgroup of patients, the median stigmatization-score was
11.2 (range 7 to 20).
These results implicated that juvenile psoriasis has a negative impact on the 
physical, emotional and social functioning of a child. Feelings of stigmatization 
were experienced by almost 65% of children interviewed for the current study and 
stigmatization-scores were nearly equal for adults in previous studies.4 Physical 
symptoms (VAS) are also experienced by a substantial proportion of patients with 
juvenile psoriasis and the scores are similar to adult patients with psoriasis in a 
general practice population.5 In contrast to the impact on pain, itch, fatigue and 
stigmatization, the median score of 2.9 can only be classified as a small effect on
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Table 1 Sam p le cha rac te ris tics
Age of respondents
Mean (SD) 12.8 years (4.25)
Range 4.3 - 17.6 years
Age of onset of psoriasis
Mean (SD) 9.4 years (5.24)
Range 2-16 years
Number of patients
Gender
Men 4
Women 11
Familial distribution
Yes (1st degree member) 9(5)
No 4
Unknown 2
SD standard deviation
the quality of life according to the scoring instructions of the CDLQI. Beattie et al 
showed a CDLQI score of 9.17, which is a moderate effect. CDLQI scores found in 
psoriasis and eczema were comparable, whereas scores for acne and urticaria 
were lower (5.4 and 6.12 respectively)2. The limitations of the current study are 
mainly contributable to the small number of patients interviewed, who also had a 
limited severity of disease. Therefore, the results displayed are only descriptive. 
In conclusion, the 15 patients interviewed had a mild psoriasis with corresponding 
stigmatization- and QoL-scores. Despite this mild psoriasis, 65% experienced 
stigmatization to a certain extent, 71% reported itch and 43% complained about 
fatigue. Clinicians should pay attention to these items, in order to initiate a 
patient-tailored treatment. Following this small pilot study, larger studies need to 
be performed to accurately address the important issues raised in the current 
study.
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Table 2 Rating of d isease-re la ted qua lity  of life
Minimum-
maximum
score
Respondents Mean (SD) Range
Severity of skin lesions 9 - 36 Children 12.3 (3.2) 10 - 22
Stigmatization 6 - 24 Children 9.4 (4.1) 6 - 20
CDLQI 0 - 30 Children 2.9 (2.9) 0 - 11
Minimum-
maximum
score
Respondents Median (IQR) Range
VAS Itch 0 - 10 Children 3.3 (0.5 - 4.6) 0 - 8
VAS Pain 0 - 10 Children 0.8 (0.0 - 1.9) 0 - 9
VAS Fatigue 0 - 10 Children 1.5 (0.5 - 6.1) 0 - 8
SD Standard deviation
CDLQI Children’s Dermatology Lite Quality Index
IQR Interquartile range
VAS Visual Analogue Scale
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Abstract
Background
Juvenile psoriasis is a chronic and incurable skin disease that affects approximately 
0.7% of children.
Objectives
To achieve more insight into the quality of life (QoL) in childhood psoriasis and to 
investigate whether disease severity scores correlate to QoL scores.
Methods
All consecutive patients with juvenile plaque psoriasis (< 18 years old) who visited 
our outpatient department were included. At baseline, the Children’s Dermatology 
Life Quality Index (CDLQI) questionnaire was completed and disease severity 
was assessed by the Psoriasis Area and Severity Index (PASI) and Physician 
Global Assessment (PGA).
Results
Thirty-nine patients were included in the study. A median CDLQI of 6 (interquartile 
range (IQR) 5 - 9) was reported. Median PASI was 6.3 (IQR 3.3 - 8.2) and median 
PGA was 2 (IQR 1 - 3). The correlation coefficient between PASI and CDLQI was 
0.47 (p = 0.003), whereas the correlation coefficient between PGA and CDLQI 
was 0.51 (p = 0.001).
Discussion
The negative effect on QoL in juvenile psoriasis was confirmed in the largest 
cohort presented up to now. The correlation between disease severity scores and 
disease-related QoL in children with psoriasis is only moderate. Therefore, both 
clinical outcome parameters (PASI, PGA) and measures of QoL (CDLQI) should 
be included in adequate, patient-oriented clinical decision making.
CDLQI scores in juvenile psoriasis
Background
Juvenile psoriasis is a chronic and incurable skin disease that effects approximately 
0.7% of children.13 Skin disease in children can have profound effects on the 
quality of life (QoL), disrupting family and social relationships, interfering with 
play, sport and school and affecting normal development.4 
The influence of juvenile psoriasis on QoL has only been described in two small 
studies.5:5 Whether there is a correlation between QoL in these children and the 
severity of their disease has never been investigated before. Therefore, it is not 
known if one can confine evaluation to only one parameter in clinical practice. 
The aim of this study was to achieve more insight in the QoL in childhood psoriasis 
and to investigate whether disease severity scores correlate with QoL scores. 
In addition, we investigated if age, gender or familiar distribution influences this 
correlation.
Methods
In this cross-sectional study, all consecutive patients with juvenile psoriasis (< 18 
years old) who visited our outpatient clinic between 1 September 2008 and
1 January 2010 were assessed at their first visit. In orderto create a homogeneous 
cohort, only patients with plaque psoriasis were included. Three patients with 
pustular psoriasis and one patient with guttate psoriasis were excluded. Patients 
with mainly nail psoriasis (n = 1) and/or arthritis (n = 1) were also excluded. 
Severity of disease was measured by the Psoriasis Area and Severity Index (PASI; 
range 0 - 72)7 and the Physician Global Assessment (PGA; range 0 - 5). Also, 
affected body surface area (BSA) was calculated. Higher scores indicate more 
severe psoriasis. Every child was scored by the same investigator. 
Disease-related QoL was assessed with a validated Dutch version of the Children’s 
Dermatology Life Quality Index (CDLQI) questionnaire.8 The total score is 
calculated by summing the score of the 10 questions, resulting in a maximum of 
30 and a minimum of 0. The higher the score, the more the QoL is impaired. 
Descriptive statistics were provided using median and interquartile range (IQR) 
values, due to the nonparametric distribution of measured variables. Correlation 
coefficients were calculated with the Spearman’s rho test. A test for comparing 
elements of a correlation matrix as described by Steiger was used to make a 
statistical comparison between correlation coefficients measured in the same
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individuals.9 For comparing correlation coefficients in different individuals the 
Fisher Z transformation was used. Statistical analysis was performed using SPSS 
16 (SPSS Inc., Chicago, IL, USA) and R version 2.10.1 (R Foundation for Statistical 
Computing, Vienna, Austria).
Results
A total of 39 patients was included in this study. The median age at baseline was
11 years (IQR 8 - 14). Gender distribution was almost equal in our cohort. Most 
patients had more than a 2.5-year history of psoriasis before visiting our clinic. 
The vast majority (74%) had one or more family members affected with psoriasis. 
Patient characteristics are depicted in Table 1.
Table 1 Patient cha rac te ris tics
Number of patients 39
Age (years), median (IQR) 11 (8 - 14)
Boys / girls, n (%) 18/21 (46/54)
Psoriasis history
Duration of psoriasis (months), 27.0 (12.0 - 73.0)
median (IQR)
Family history of psoriasis, n (%) 29 (74)
Psoriasis baseline assessments
CDLQI, median (IQR) 6 (5 - 9)
PASI, median (IQR) 6.3 (3.3 - 8.2)
PGA, median (IQR) 2 (1 - 3)
BSA (%), median (IQR) 6.8 (2.3 - 13.5)
IQR Interquartile range 
CDLQI Children’s Dermatology Lite Quality Index
PASI Psoriasis Area and Severity Index
PGA Physician Global Assessment
BSA Body Surface Area
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The median CDLQI score was 6 (IQR 5 - 9). The following median severity scores 
were found: PASI 6.3 (IQR 3.3 - 8.2), PGA 2 (IQR 1 - 3) and BSA 6.8% (IQR 2.3 - 13.5). 
The correlation coefficient between PASI and CDLQI was 0.47 (p = 0.003), 
whereas the correlation coefficient between PGA and CDLQI was 0.51 (p = 0.001). 
According to the test for comparing elements of a correlation matrix, the difference 
between these correlation coefficients (i.e. 0.47 and 0.51) was not significant in 
our population. The distribution of individual cases is displayed in Figures 1 and
2. Subanalyses for correlation coefficients were performed on different groups 
according to gender, familiar predisposition, parts of the body that were affected, 
age at baseline and age of onset of psoriasis. No significant differences were 
found between the different groups using the Fisher Z transformation.
Figure 1 Children's Dermatology Life Quality Index (CDLQI) in relation 
to Psoriasis Area and Severity Index (PASI). A regression line 
is shown.
PASI
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Figure 2 Children's Dermatology Life Quality Index (CDLQI) in relation to 
Physician Global Assessment (PGA). A regression line is shown
PGA
Discussion
Regarding the impact of chronic diseases on the QoL, children are an especially 
vulnerable group because the developmental changes in this phase of life are 
substantial. It has been reported that the QoL of children with psoriasis is even 
worse than in diabetes and epilepsy in childhood.5 Information regarding factors 
influencing QoL in children with psoriasis is gathering over time. Eventually, this 
will give us tools for combined treatment focused on the patient’s disease and 
QoL.
In this study the negative effect on the QoL of juvenile psoriasis is demonstrated. 
Two previous studies have reported CDLQI scores of children with psoriasis.
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In both studies, patients attending a (paediatric) dermatology clinic were Included. 
In the validation study of the CDLQI questionnaire, 25 patients with psoriasis were 
questioned.5 The mean CDLQI score was 5.4 (SD 5.0; range 0-18). In another 
study, 29 juvenile patients with psoriasis completed the CDLQI questionnaire.5 
Their mean score was 9.17 (SD 7.83; range 0 - 27). Unfortunately, no clinical 
severity scores have been reported In either study, nor were correlations shown. 
The CDLQI score of 6 found In our cohort Is In line with the previous studies and 
confirms the high Impact of this disease on dally life.
To Investigate the relation between disease severity and Impact of disease, 
correlation coefficients were calculated. In the present study, the PGA had a 
higher correlation coefficient with the CDLQI (0.51) than had the PASI (0.47), 
although this difference was not significant. Both disease severity measures 
showed a moderate correlation with the QoL scores. This Is roughly comparable 
with previous studies In adults with psoriasis which have also shown a poor to 
moderate correlation (I.e. range 0.15 - 0.4).1013 This moderate correlation could be 
explained by the fact that perception of QoL may depend not only on disease 
severity, but also on age, gender, social class, ethnicity, education, anxiety level, 
and the ability to minimize or exaggerate symptoms.14 Nevertheless, a significant 
Influence of age or gender In the perception of QoL In our cohort could not be 
found. Although there Is not a good correlation between absolute values of the 
PASI and DLQI, the results of several clinical trials In adults Indicate that reduction 
of physical severity Is associated with Improvement of QoL.15 Even though this Is 
still a relatively small sample size, the present study contributes valuable additional 
Information on QoL In juvenile psoriasis.
In conclusion, the negative Impact on QoL In juvenile psoriasis was confirmed In 
the largest cohort presented up to now. As the correlation between disease 
severity scores and disease-related QoL In children with psoriasis Is only 
moderate, both clinical outcome parameters (PASI, PGA) and measures of QoL 
(CDLQI) should be Included In adequate, patient-oriented clinical decision making.
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Summary and conclusions
The present thesis intended to gain more insight in several aspects of childhood 
psoriasis. Therefore, six aims were formulated in Chapter 1.
In this chapter, a summary of the major conclusions of the presented articles will 
be given and discussed. In addition, practical advices for physicians treating 
children with psoriasis will be given, based on the most recent insights and evidence.
Aim la)
To further explore the epidemiology and clinical features of childhood 
psoriasis in The Netherlands
This aim was addressed by means of three studies presented in Chapter 2.
In Chapter 2.2, a prevalence of childhood psoriasis of 0.37% was found for the 
age group from 0 to 10 years old. The prevalence in the age group from 11 to 19 
years old was 1.09%. The total prevalence of psoriasis in children under 20 years 
old was 0.7%. These figures are highly comparable with those found in other 
European studies (United Kingdom: 0.55% 0 - 9 years and 1.37% 10 - 19 years1; 
Germany 0.37% 0 - 9 years and 1.01% 10 - 19 years2). In the German study, the 
total prevalence of psoriasis in children up to 18 years was 0.71 %.2 If the results of 
our study are extrapolated across the Dutch population, a total number of 27 500 
children with psoriasis should be living in The Netherlands.
In Chapter 2.1, 37.1% of patients reported an onset of the disease before the age 
of 18 years, which is comparable with literature which reports 27 - 50%.3 9 If this 
number stated by the patients is correct, the supposed number of children with 
psoriasis in The Netherlands is even higher: 140 000 children. Several explanations 
for this difference in number of children with psoriasis between Chapter 2.1 and 
Chapter 2.2 can be considered. It may be a matter of overestimation by previous 
literature, as well as an overestimation of the patients who filled out the 
questionnaire (e.g. due to a recall bias). There could also be a selection bias 
present in the response group, because patients with childhood onset of psoriasis 
might be more inclined to fill out and return the questionnaire. It is also possible 
that the numbers from Chapter 2.2 are an underestimation of the actual prevalence, 
because this number only reflects the patients that are currently under the care of 
a general practitioner. On the contrary, the studies from the United Kingdom and 
Germany calculated their numbers from nationwide databases which contain 
information of 1.3 million and more than 8 million patients, respectively.
In Chapter 2.1 only a single peak in age of onset of psoriasis was demonstrated 
around the age of 15 - 19 years. This single peak was also found by other
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investigators.4:10 in one study the prevalence increased in an approximately linear 
matter.2 This is in contrast to the research performed by Henselerand Christophers, 
which showed a dual peak at the ages 16-22 years and 60 years.11 
Gender distribution was also investigated. In Chapter 2.2, there was a male to 
female ratio of children with psoriasis of 1.6 : 1 in the general practitioner 
population, whereas there was a ratio of 1 : 1.3 in the patient population of the 
dermatologists. In Chapter 2.3, a cohort of Dutch children with psoriasis was 
compared with a Singaporean cohort of children with psoriasis. In the Dutch 
children an equal gender distribution of psoriasis was seen (male to female ratio 
= 1 : 1.1), whereas in Singaporean children there was a slight tendency towards a 
preponderance for women (male to female ratio = 1 : 1.4). Overall, one can 
conclude that mainly an equal gender distribution was found, which is consistent 
with most of the published literature.10:1217 Nevertheless, some cohorts consist of 
more girls than boys with childhood psoriasis.18 22
A familial distribution was revealed in 50.3 - 73.3% of the Dutch patients with 
juvenile psoriasis (Chapter 2.2 and 2.3). In contrast, only 13.6% of Singaporean 
patients had a family member with psoriasis (Chapter 2.3). The disparity in 
familial distribution between Caucasian and predominantly Han Chinese patients 
could be due to genetic differences. An additional reason on which genetic 
differences as a causal factor can be proposed is that there is a difference in 
familial distribution across different parts of the world. The highest rates of familial 
distribution are found in European and Australian populations13-1 and the lowest 
in Indian and Chinese communities12117.
The occurrence of several clinical features in childhood psoriasis was examined 
in our own cohort of psoriatic children (Chapter 2.3). The most frequently seen 
type of psoriasis was plaque psoriasis (88.9%), followed by pustular psoriasis 
(6.7%) and guttate psoriasis (2.2%). The most frequently involved sites were the 
scalp (88.9%) and limbs (86.7%). Intertriginous areas and the face were both 
involved in 24.4% of the patients. Nail changes were seen in 22.2% of the patients, 
with pitting as the most common abnormality. Arthritis was present in 2.2% of the 
children. Pruritus was reported by 80% of the patients. All these data are roughly 
comparable with percentages from previous reports.10;12~24 In only 3.3% of the 
children precipitating factors were found. The most common factor was stress 
(66.7%), followed by infections (20%).
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Aim lb)
To compare differences and similarities between childhood onset 
psoriasis and adult onset psoriasis
In Chapter 2.1, a comparison was made between childhood onset psoriasis 
(COP) and adult onset psoriasis (AOP). A higher percentage of women was found 
In the COP-group (62.9%) than In the AOP-group (45.2%). A correlation of COP 
and a high body mass Index (BMI) at adult age could not be demonstrated. In 
fact, the mean BMI was even slightly lower In patients with COP compared with 
AOP (26.2 versus 26.8 kg/m2). Nevertheless, recent studies In children with 
psoriasis have demonstrated that their BMI Is often too high as compared with 
WHO standards.25 27 In adulthood, the most frequently reported type was plaque 
psoriasis In both COP and AOP patients. Guttate and erythrodermlc psoriasis 
seemed to occur more often In adults with COP than In adults with AOP. In the 
majority of patients with COP, the type of psoriasis at onset remains the same 
when the patient grows up. Joint and nail Involvement were seen In equal 
percentages In the COP- and AOP-group.
Psoriasis In adulthood was not more severe In patients with COP than In patients 
with AOP. Both scores of the Self-Admlnlstered Psoriasis Area and Severity Index 
(SAPASI) and Physician Global Assessment (PGA) were not significantly different 
In the COP- and AOP-group at adult age. In addition, there was no difference In 
most potent treatment prescribed at adult age between the COP- and AOP-group. 
This Implies that the course of COP Is not worse than that of AOP.
A remarkable observation was that the diagnosis delay (time from onset of 
symptoms to final diagnosis) was significantly longer for patients with COP than 
AOP. In COP, the delay In diagnosis was 3.1 years, whereas In AOP this was 1.5 
years. This could be due to the fact that childhood psoriasis can mimic nummular 
eczema and often Itches. Also, because of the relatively low prevalence In 
childhood, It Is usually not the first diagnosis that Is suspected by a physician.
Aim Ila)
To obtain an overview of efficacy and safety of treatment options in 
childhood psoriasis
To give an evidence-based overview of available treatments In childhood psoriasis, 
a systematic review was performed (Chapter 3.1). In Chapter 3.2, research was 
performed on short-contact dlthranol therapy, a classic nearly forgotten antlpsorlatlc
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treatment option. The major conclusions on the efficacy and safety of these 
treatments will now be described separately for each treatment. For references 
the reader is referred to Chapter 3.
Efficacy and safety of treatments
Unfortunately, none of the articles described in the review in Chapter 3.1 reported 
data on long-term safety profiles. The median follow-up duration of dithranol 
treatment in Chapter 3.2 was 12.5 months, describing an intermediate duration 
of follow-up.
Topical corticosteroids: Only three studies could be included in the review for 
evaluation, each with a treatment-period of two to three weeks. It seems that 
halobetasol cream 0.05% and clobetasol propionate emulsion 0.05% are 
efficacious treatments in childhood plaque psoriasis. Reported side effects of 
halobetasol cream 0.05% and clobetasol propionate emulsion 0.05% were 
relatively mild (mild skin atrophy, burning sensation at the application site) in the 
treatment period of two weeks.
Vitamin D3 analogues: Calcipotriol is an effective treatment option for childhood 
plaque psoriasis as has been proven by several studies among which a random- 
ized-controlled trial. Less research has been performed on calcitriol, but it seems 
to be an effective treatment. Calcipotriol is a reasonably well tolerated treatment 
option for childhood plaque psoriasis. The most common side effect was irritation. 
Calcitriol also seems to have mild side effects. Long-term side effects were not 
described.
Calcineurin inhibitors: Tacrolimus 0.1% is an effective and safe therapeutic option 
for short-term treatment of facial and intertriginous childhood psoriasis. The only 
side effect reported was pruritus. Again, long-term safety was not described. No 
conclusion could be drawn for the use of pimecrolimus due to the small number 
of patients in the included studies.
Dithranol: The reviewed literature shows that dithranol is an effective treatment. 
This was confirmed by a study performed at our department among 60 patients. 
Short-contact dithranol treatment was demonstrated to be an effective treatment 
modality in 73% of treated children with psoriasis. A median treatment period of 
two months was needed to establish a median duration of remission of 5.5 months
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(Chapter 3.2). Dithranol is a treatment in childhood psoriasis with a good margin 
of safety for short-term use according to the review. Mild transient skin irritation 
and staining were the most frequently reported side effects (Chapter 3.1). In our 
own cohort (Chapter 3.2), skin irritation was also reported, nevertheless no 
severe side effects were seen during the follow-up period (median 12.5 months).
Phototherapy: Good results in the treatment of plaque and guttate psoriasis in 
childhood are found with narrowband (NB)-ultraviolet (UV) B radiation according 
to the reviewed literature. The treatment with NB-UVB shows comparatively mild 
side effects (e.g. erythema) for the relative short treatment duration studied. 
Although there are no studies documenting the long-term safety of UVB 
phototherapy in childhood psoriasis, the risk of photo ageing and carcinogenesis 
should be considered. As only four patients have been described who were 
treated with psoralen plus UVA radiation (PUVA), a solid conclusion about the 
efficacy and safety of PUVA treatment could not be drawn.
Antibiotics: The efficacy of the use of antibiotics in childhood guttate psoriasis 
remains controversial as two studies found no effect of this treatment and three 
studies showed a good to excellent effect. The safety of the use of antibiotics in 
childhood guttate psoriasis was not sufficiently described.
Retinoids: Previously published literature has shown that etretinate is an effective 
treatment for pustular and erythrodermic psoriasis. However, etretinate is not 
available anymore. Unfortunately, the use of acitretin has not been sufficiently 
investigated in childhood psoriasis; therefore no conclusions could be drawn. 
Nevertheless, a treatment with acitretine can be attempted in case of pustular or 
erythrodermic psoriasis because both treatment modalities (etretinate and 
acitretin) have the same mode of action, as acitretin is the active metabolite of 
etretinate. Side effects are frequently seen during the treatment with retinoids. 
Cheilitis was often described as a side effect, as well as pruritus and hair loss. No 
conclusions could be drawn from the review on the safety of this drug in children, 
because of the lack of evidence. Toxic, irreversible musculoskeletal side effects 
(including osteoporosis, periosteal plucking, formation of slender long bones and 
premature epiphyseal closure) have been associated with chronic use of 
high-dose systemic retinoids for other indications.28-9 However, these adverse 
musculoskeletal side effects have not been associated with lower doses typically 
used to treat psoriasis and keratinization disorders, even when used for periods
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longer than 10 years.30 33 When retinoids are prescribed to fertile women It should 
be discussed that this drug Is known to be a potent teratogen and pregnancies 
should be avoided for at least three years after discontinuing therapy.34
Ciclosporin: The efficacy of clclosporln treatment In childhood psoriasis Is 
ambiguous. In previously published literature, five patients have been treated with 
good effect, but four patients did not show any response. A solid conclusion 
could therefore not be drawn. This also applies to the safety Issues which were 
also sparsely described. It Is known from literature that the main safety concern 
of clclosporln Is potential nephrotoxicity. Since Irreversible Interstitial renal fibrosis 
has been reported,35 renal function should be closely monitored.
Methotrexate: Methotrexate Is an effective treatment option In moderate to severe 
childhood psoriasis; the largest body of evidence Is available for plaque psoriasis, 
but the use has also been described In other types of psoriasis. Short-term side 
effects of methotrexate In the treatment of juvenile psoriasis are usually mild and 
can be treated very well. The side effects Include mild to severe nausea and 
vomiting. Also a transient minor elevation of liver enzymes was repeatedly found. 
Data regarding long-term safety of the use of methotrexate for childhood psoriasis 
Is lacking. However, In juvenile Idiopathic arthritis (J I A), this drug Is often used for 
long periods of time and has a track record of safe and effective use.35 There has 
been very little evidence to substantiate hepatotoxlclty or clinical significant bone 
marrow suppression In children treated with methotrexate for JlA.37-42
Biologies: As has been shown In a large randomlzed-controlled trial (and several 
case reports), etanercept Is an effective biologic In the treatment of plaque type 
childhood psoriasis. The most common short-term side effects of etanercept during 
the treatment period described In childhood psoriasis were upper respiratory 
Infections, headache and nasopharyngitis. A recent study showed no new safety 
Issues after 144 weeks of treatment In children older than eight years with severe 
childhood plaque psoriasis compared with the previously published randomized 
controlled trial.43 Previous studies on the safety of etanercept In patients with juvenile 
Idiopathic arthritis report few adverse events and a low rate of serious adverse events 
after eight years of continuous treatment with etanercept, without an Increase In rates 
of serious adverse events over time.44:45 However, long-term safety data are not 
available. Based on only four case reports, a solid conclusion on the efficacy and 
safety of the use of Infliximab In children with psoriasis could not be drawn.
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To create an evidence-based algorithm for the treatment of childhood 
psoriasis
Based on Chapter 3, the following treatment algorithm was constructed:
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Summary and conclusions
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The treatment of choice in mild or moderate juvenile psoriasis should be 
calcipotriol. If necessary, this can be combined with mild to moderate topical 
corticosteroids. Tacrolimus can be additionally prescribed in case of treatment- 
resistant flexural and/or facial psoriasis. If this treatment regimen is not effective, 
or if psoriasis is moderate to severe, treatment with dithranol is recommended. If 
these treatments are not efficacious enough, a short treatment with NB-UVB can 
be considered in adolescents. Even though controversial, the use of antibiotics 
can be considered in case of guttate psoriasis and evidence of a streptococcal 
infection by means of a throat culture.
If systemic treatment is necessary, methotrexate is regarded as the therapy of 
choice. In cases of pustular and erythrodermic psoriasis retinoids can be 
considered. Treatment with ciclosporin should only be deliberated in exceptional 
cases. Etanercept should be used if the above described protocol is insufficient 
to control the disease.
Aim Ilia)
To get more insight in the psychological burden of psoriasis in children
To assess the burden children with psoriasis have to cope with, research was 
performed in children and adults with childhood onset psoriasis (COP).
In Chapter 4.1, 568 adults with COP were asked to (retrospectively) estimate their 
quality of life in childhood. Limitations were especially noted on recreational and 
social activities. Fifteen to 30% of the patients even indicated a large influence of 
the disease on these activities. Recreational and social activities are part of the 
social development domain, which is one of the developmental milestones in a 
child's life.
In Chapter 4.2, a pilot study in 15 juvenile patients with a mild psoriasis was 
described. In the semi-structured interviews approximately half of the children 
said they were bullied or called names. One girl even indicated that other children 
did not want to play with her because of the skin lesions. Questions from others 
on contagiousness of the lesions were also frequent. Scores on questionnaires 
showed a mild effect on quality of life (mean Children’s Dermatology Life Quality 
Index (CDLQI) score 2.9). Nevertheless, 65% experienced stigmatization, 71% 
reported itch and 43% complained about fatigue. These scores are comparable 
with scores in adult patients with psoriasis.45:47
Additional information on CDLQI scores was gathered in Chapter 4.3. In this 
chapter a study is presented in 39 juvenile psoriasis patients. The median CDLQI
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score was 6. This is in line with previous studies which report scores of 5.4 and 
9 . 2.48:49 Furthermore, these scores are also comparable with results from studies 
in adult patients with psoriasis.50:51 It was also investigated if disease severity 
scores (Psoriasis Area and Severity Index (PASI) and Physician Global Assessment 
(PGA) scores) correlate with quality of life scores (CDLQI scores). Both disease 
severity scores showed only a moderate correlation with quality of life scores. This 
could be explained by the fact that perception of quality of life may depend not 
only on disease severity, but also on age, gender, social class, ethnicity, education, 
anxiety level and the ability to minimize or exaggerate symptoms.52 From the study 
in Chapter 4.3, the conclusion can be drawn that juvenile psoriasis has a negative 
effect on quality of life and both disease severity scores and measures of quality 
of life should be taken into account when treating a child with psoriasis.
Aim lllb)
To compare the burden of psoriasis as experienced in childhood to the 
burden in adulthood
The study described in Chapter 4.1 was set up to achieve this aim. The answers 
of the 1762 patients who participated in this study were analyzed after respondents 
were divided into two groups: childhood onset psoriasis (COP; onset of the 
disease before the age of 18 years) and adult onset psoriasis (AOP; onset of the 
disease from the age of 18 years). The COP group had a mean Dermatology Life 
Quality Index (DLQI) score of 12.8 in their youth (<18 years). On the contrary, their 
current quality of life was rated with a mean DLQI score of 6.8. The severity of 
disease in childhood was rated slightly worse than in adulthood. The two-fold 
decrease of the mean DLQI score in adulthood as compared with childhood 
could be justified by several explanations. The impact of psoriasis in childhood 
could be genuinely bigger than in adulthood. On the other hand, in prospective 
studies that have been performed the CDLQI scores of children with psoriasis are 
between 2.9 and 9.2.48:49:53:54 Another possibility is that children rate their quality of 
life differently than adults and that CDLQI and DLQI scores cannot be compared. 
Besides that, a recall bias could be present. Another explanation could be that 
although quality of life scores in childhood are moderate, the same adults think that 
their quality of life in the past is affected more than they had realized at that time. 
The current quality of life of patients with COP and AOP was also a subject of the 
study described in Chapter 4.1. Here it was shown that the current quality of life of 
(adult) patients does not differ between COP patients and AOP patients with
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comparable severity scores. Therefore, the conclusion can be drawn that quality
of life and severity of disease In adulthood are not determined by the age of onset
of psoriasis.
Main conclusions of this thesis:
Epidemiology (Chapter 2)
• Childhood psoriasis has an overall prevalence of 0.7% In The Netherlands, 
which means that there should be approximately 27 500 children with psoriasis 
In The Netherlands. More precisely, In the first age decade the prevalence Is
0.37%; In the second age decade 1.09%.
• Of the adult patients with psoriasis, 37.1% reports an onset of disease before 
the age of 18 years.
• Dutch juvenile psoriasis patients report a familial distribution In 50.3 - 73.3%. 
On the contrary, In only 13.6% of Singaporean children with psoriasis a familial 
distribution Is noted.
• The most frequently seen type of childhood psoriasis In the Dutch cohort Is 
plaque psoriasis (88.9%), followed by pustular psoriasis (6.7%) and guttate 
psoriasis (2.2%).
• Scalp (88.9%) and limbs (86.7%) are the most often affected body parts In 
children with psoriasis.
• Pruritus Is frequently a complaint of children with psoriasis (80% of the 
cases).
• A correlation between childhood onset psoriasis and a high body mass Index 
at adult age could not be found.
• The type of psoriasis at onset often remains the same throughout life In 
childhood onset psoriasis patients.
• The course of childhood onset psoriasis Is not worse than that of adult onset 
psoriasis.
• Delay In diagnosis Is on average twice as long In childhood onset psoriasis as 
In adult onset psoriasis.
Treatments (Chapter 3)
• Only two randomized controlled trials have been performed on treatments for 
childhood psoriasis: one with calcipotriol and one with etanercept.
• A rough summary of the proposed treatment algorithm Is as follows: first,
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calcipotriol with or without topical corticosteroids, followed by dithranol. 
Methotrexate is considered to be the systemic treatment of choice. The 
extended treatment algorithm can be found on page 155.
• Short-contact dithranol therapy is an effective and safe treatment option for 
childhood psoriasis and should be attempted first before prescribing systemic 
medication.
Quality of life (Chapter 4)
• The burden of psoriasis in children is substantial and mainly affects recreational 
and social activities.
• Disease severity scores show a moderate correlation with quality of life scores, 
therefore both scores should be taken into account when deciding on the 
treatment strategy in childhood psoriasis.
• Quality of life in adulthood is not determined by age of onset of psoriasis.
Practical clinical advises:
As has been demonstrated in this thesis, childhood psoriasis is a relatively 
frequently seen disease. Because it can mimic nummular eczema, it is very 
important for physicians to consider childhood psoriasis in case of an itching, 
fine-scaled, nummular, erythematous skin condition (especially if the scalp is 
affected). The occurrence of psoriasis in the patient’s family can point in the right 
direction, although in Asian children this positive family history is often absent. 
Childhood psoriasis can have an important influence on a child’s life. Therefore, 
not only clinical severity should be taken into account when deciding on a 
treatment strategy, but also the impact of the disease on the quality of life of the 
child. As the correlation between these two aspects is only moderate, both a 
severity score (e.g. PASI, PGA) and a quality of life score (e.g. CDLQI) should be 
assessed. Preferably, these assessments should be made at regular time intervals 
to provide an overview in time of the health status of the child. Based on the 
repeated quality of life measurements and severity scores, the steps of the 
proposed treatment algorithm (page 155) can be followed. By doing so, treatment 
steps will be tailored for each individual child, and therefore optimal care will be 
provided in the treatment of childhood psoriasis.
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Nederlandse samenvatting
Psoriasis is een chronische, inflammatoire huidziekte die zich bij ongeveer 30% 
van de patiënten manifesteert op de kinderleeftijd. Echter, de beschikbare 
literatuur over de ziekte in deze leeftijdscategorie is erg beperkt. Een overzicht 
hiervan wordt gegeven in hoofdstuk 1.
In dit proefschrift zijn nieuwe gegevens verzameld omtrent juveniele psoriasis, 
om zo te komen tot een beter begrip van de ziekte. Daaruit voortvloeiend zijn 
behandelstrategieën voor kinderen met psoriasis opgesteld.
Dit proefschrift beschrijft drie verschillende aspecten van juveniele psoriasis:
1. Epidemiologie en klinische kenmerken (hoofdstuk 2)
2. Behandelopties (hoofdstuk 3)
3. Kwaliteit van leven (hoofdstuk 4)
Hoofdstuk 2 bestaat uit drie studies. In hoofdstuk 2.1 worden de resultaten van 
een enquête onder 1926 volwassen patiënten beschreven. De respondenten 
werden verdeeld in twee groepen: patiënten met psoriasis die was ontstaan op 
de kinderleeftijd (leeftijd < 18 jaar) en patiënten met psoriasis die was ontstaan 
op de volwassen leeftijd (leeftijd > 18 jaar). De verschillen en overeenkomsten 
tussen deze twee groepen worden gepresenteerd. Middels een enquête onder 
huisartsen en dermatologen (hoofdstuk 2.2) is een prevalentie-cijfer vastgesteld 
van juveniele psoriasis in Nederland. Uit de literatuur is bekend dat er verschillen 
bestaan in klinische kenmerken en familiair voorkomen tussen verschillende 
bevolkingsgroepen wereldwijd. Daarom werd in hoofdstuk 2.3 het Nijmeegse 
juveniele psoriasis cohort vergeleken met een cohort van kinderen met psoriasis 
uit Singapore.
Het doel van hoofdstuk 3 was om de beschikbare behandelingen voor juveniele 
psoriasis te evalueren en een behandelalgoritme op te stellen. Daarom werd een 
systematisch literatuuronderzoek verricht (hoofdstuk 3.1). Tevens werd er 
aanvullend een onderzoek gedaan naar de effectiviteit en veiligheid van 
kort-contact dithranol behandeling (hoofdstuk 3.2) om de plaats van deze 
behandelmogelijkheid in het behandelalgoritme vast te stellen. Het behandel­
algoritme is te vinden op pagina 155 van dit proefschrift.
De kwaliteit van leven bij kinderen met psoriasis staat centraal in hoofdstuk 4. 
Allereerst is onderzocht hoe de kwaliteit van leven van deze kinderen zich
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ontwikkelt in de loopvan het leven. Daarnaast werd vastgesteld opwelke gebieden 
psoriasis de meeste invloed heeft gehad op de kinderleeftijd (hoofdstuk 4.1). 
Ook zijn er interviews met juveniele psoriasis patiënten verricht om deze aspecten 
verder uit te diepen (hoofdstuk 4.2). In hoofdstuk 4.3 is de correlatie onderzocht 
tussen scores waarbij de uitgebreidheid van de psoriasis wordt vastgelegd (bijv. 
PASI, PGA) en kwaliteit van leven scores (bijv. CDLQI).
In hoofdstuk 5 worden de bevindingen per hoofdstuk samengevat en 
bediscussieerd.
De belangrijkste conclusies van dit proefschrift:
Epidemiologie (hoofdstuk 2)
• Juveniele psoriasis heeft een totale prevalentie van 0.7% in Nederland, wat 
neerkomt op ongeveer 27 500 kinderen met psoriasis in Nederland. In de leef­
tijdscategorie van 0 tot 10 jaar is de prevalentie 0.37%, in de leeftijdscategorie 
van 11 tot 19 jaar 1.09%.
• Van de volwassen patiënten met psoriasis geeft 37.1% aan dat de huidklachten 
vóór het 18e levensjaar begonnen zijn.
• In Nederland is er bij 50.3 tot 73.3% van de juveniele psoriasis patiënten sprake 
van een belaste familieanamnese voor psoriasis. Bij kinderen uit Singapore 
met psoriasis is er in slechts 13.6% sprake van het familiair voorkomen van 
psoriasis.
• Het meest voorkomende type psoriasis bij kinderen in het Nederlandse cohort 
is plaque psoriasis (88.9%), gevolgd door psoriasis pustulosa (6.7%) en 
psoriasis guttata (2.2%).
• De hoofdhuid (88.9%) en extremiteiten (86.7%) zijn de meest aangedane 
lichaamsdelen bij kinderen met psoriasis.
• Jeuk komt voor bij ongeveer 80% van de kinderen met psoriasis.
• Een verband tussen psoriasis ontstaan op de kinderleeftijd en een hoge body 
mass index op volwassen leeftijd is niet aangetoond.
• Het type psoriasis dat ontstaat op de kinderleeftijd blijft vaak onveranderd 
gedurende het gehele leven.
• Het beloop van juveniele psoriasis is niet ernstiger dan die van psoriasis 
ontstaan op de volwassen leeftijd.
• De tijd tussen het ontstaan van klachten en het stellen van de diagnose is
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gemiddeld twee keer zo lang bij juveniele psoriasis in vergelijking met psoriasis 
ontstaan op volwassen leeftijd.
Behandelingen (hoofdstuk 3)
• Er zijn slechts twee gerandomiseerde gecontroleerde studies verricht naar het 
effect en de veiligheid van medicamenteuze behandelingen bij kinderen met 
psoriasis: één met calcipotriol en één met etanercept.
• Een korte samenvatting van het behandelalgoritme is als volgt: geadviseerd 
wordt te starten met calcipotriol met of zonder topicale corticosteroïden, 
gevolgd door dithranol. Methotrexaat wordt beschouwd als de eerste keus 
systemische behandeling. Het volledige behandelalgoritme is beschreven op 
pagina 155 van dit proefschrift.
• Kort-contact dithranol therapie is een effectieve en veilige behandeling voor 
psoriasis bij kinderen en dient eerst geprobeerd te worden alvorens over te 
gaan op systemische medicatie.
Kwaliteit van leven (hoofdstuk 4)
• Psoriasis bij kinderen heeft een grote invloed op de kwaliteit van leven, met 
name op recreatieve en sociale activiteiten.
• Ziekte-ernst scores hebben een matige correlatie met kwaliteit van leven 
scores, waardoor er dus rekening gehouden dient te worden met beide scores 
in de besluitvorming over de te volgen behandelstrategie.
• Kwaliteit van leven op volwassen leeftijd wordt niet bepaald door de leeftijd 
waarop de psoriasis ontstaan is.
Praktische klinische adviezen:
Zoals is aangetoond in dit proefschrift is juveniele psoriasis een relatief vaak 
voorkomende huidziekte. Omdat de huidafwijking kan lijken op nummulair 
eczeem is het erg belangrijk voor artsen om de diagnose juveniele psoriasis te 
overwegen in geval van een jeu kende, fijn schilferende, nummulaire, erythemateuze 
huidafwijking (vooral als de hoofdhuid is aangedaan). Het voorkomen van 
psoriasis in de familie van de patiënt kan wijzen in de richting van de juiste 
diagnose, hoewel bij Aziatische kinderen een belaste familieanamnese vaak 
afwezig is.
Juveniele psoriasis kan van grote invloed zijn op het leven van een kind. Daarom
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moet niet alleen de ernst van de psoriasislaesies in ogenschouwworden genomen 
bij de beslissing over een behandelstrategie, maar ook de impact van de ziekte 
op de kwaliteit van leven van het kind. Omdat de correlatie tussen deze twee 
aspecten slechts matig is, zouden zowel een ziekte-ernst score (bijv. PASI, PGA) 
en een kwaliteit van leven score (bijv. CDLQI) moeten worden afgenomen. Bij 
voorkeur dienen deze scores te worden bepaald op regelmatige tijdstippen om 
een overzicht van de totale (lichamelijke en psychische) gezondheidstoestand 
van het kind in de tijd te verkrijgen.
Vervolgens kunnen de stappen van het behandelalgoritme (pagina 155) worden 
gevolgd op geleide van de ziekte-ernst scores en de kwaliteit van leven scores 
om zo te komen tot de meest optimale zorg voor patiënten met juveniele 
psoriasis.
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Vrienden en familie, bedankt voor de gezelligheid en jullie interesse in mijn 
werkzaamheden. In het bijzonder gaat mij dank ook uit naar Edith en Stef; tijdens 
de weekeinden in Rees is een groot deel van dit boekje samengesteld.
Merel, Janneke en Kim (mijn oud-Kroolus collega’s), bedankt dat ik af en toe bij 
jullie mijn hart kon luchten, voor jullie vriendschap, gezelligheid, interesse en 
steun. Jullie zijn me ontzettend dierbaar.
Mark, lief broertje, voor de 2e keer genoemd worden in het dankwoord, dan moet 
je wel erg belangrijk zijn! Maar dat is natuurlijk ook zo. Gelukkig hebben we 
allebei een ander vakgebied gekozen, scheelt weer wat medische en juridische 
consultkosten. Bedankt voor je support.
Lieve papa en mama, bedankt dat jullie altijd achter me staan en voor jullie 
vertrouwen en liefde.
Maar op de belangrijkste plaats, Gijs, Liefie, bedankt voor je onvoorwaardelijke 
liefde, steun en rotsvaste vertrouwen in mij. Zonder jou was het me nooit gelukt. 
Ondanks je eigen promotietraject, heb jij dit boekje vaker gelezen dan wie ook. 
Bedankt voor al je correcties. Toch best handig om als reumatoloog ook iets van 
kinderpsoriasis te weten. Nu nog de dermatoloog die iets van artrose weet, maar 
die volgt vast ook snel! One down, one to go!
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